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Abstract
Androgen receptor (AR)-regulated genes contribute to the initiation and progression of prostate
cancer. Receptor signaling persists and plays a pivotal role in late-stages of the disease, for which
there is currently no treatment. Thus, there is a need to understand the mechanisms regulating AR
function as a means to identify drug targets for potential therapeutics. The FKBP52 cochaperone
has emerged in recent years as a regulator of AR activity that is functionally linked in the AR
signaling pathway. FKBP52 is a known positive regulator of AR and believed to interact with AR
at its binding function 3 surface (BF3), a site located on AR’s hormone binding domain. We
previously demonstrated that FKBP52 and an AR co-activator, β-catenin, interact directly in vitro
and act in concert to promote up-regulation of both hormone-independent and dependent AR
signaling. Here, we have demonstrated the amino acids on each protein necessary to regulate AR
activity in vitro- FKBP52 relies on the proline-rich loop situated above its catalytic pocket while
β-catenin requires key amino acids found in its armadillo repeat domain. We also show that Bag1L, a cochaperone which binds AR BF3 and aids in AR folding and maturation, interacts directly
with β-catenin, suggesting multiple distinct complexes involving β-catenin may regulate AR
activity. Using the CRISPR/Cas9 system, we knocked out FKBP52 from 22Rv1 cells and found
that these cells require higher hormone concentrations for receptor induction and they fail to form
tumors in mouse xenografts. ChIP-seq and RNA-seq of these cells revealed marked differences in
AR DNA binding sites as well as distinct changes in gene expression, signifying FKBP52
influences AR activity significantly more than was previously known. FKBP52 was validated as
a possible therapeutic target through the use of small molecules directed against the cochaperone,
resulting in the inhibition of FKBP52-specific AR activity.
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Chapter 1: Introduction

1

1.1 ANDROGEN RECEPTOR STRUCTURE AND FUNCTION

The androgen receptor (AR) is a hormone-activated transcription factor that is essential for
the prostate's growth, development, and function and exerts its function from embryogenesis into
adulthood (1–3). AR is a steroid hormone receptor (SHR) and is a member of the nuclear receptor
superfamily. Based on similarities in the sequences of the DNA-binding domain and ligandbinding domain, AR is categorized into the same subfamily as the following steroid hormone
receptors: glucocorticoid (GR), estrogen (ER), progesterone (PR), and mineralocorticoid (MR)
(4). These steroid hormone receptors are an evolutionarily conserved group of transcription factors
that utilize cholesterol-derived ligands to exert their functions at target tissues. Their proper
regulation and transactivation of target genes is integral in maintaining an array of physiological
processes including but not limited to energy metabolism, electrolyte balance, and sexual
differentiation (4).
The gene for AR is found on the X chromosome and codes for a 919 amino acid protein
composed of 8 exons with a mass of approximately 110 kDa (2). The modular structure of AR is
organized into 4 domains, each of which is structurally and functionally distinct: a highly variable
NH2-terminal domain (NTD), a conserved DNA binding domain (DBD), a short hinge region, and
a conserved COOH-terminal ligand-binding domain (LBD) (2, 5). Within the NH2 and the COOH
terminal domains are also specialized regions necessary for optimal transcriptional activation of
the receptor (3, 5).
The amino-terminal domain (NTD) is a relatively large region of the androgen receptor,
spanning almost half the length of the receptor. It is coded by exon 1 and is a highly disordered
and poorly conserved domain (5). The NTD is considered to be a constitutively active domain,
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since it is capable of activating transcription independently of an androgenic stimulus due to the
presence of a transcriptional activation function domain, termed AF-1 (2, 3, 6). Although the NTD
is well known to be undefined with high primary sequence variability among individual receptors,
recent mutagenesis studies have revealed that a WxxLF motif within the AF-1 is required for AR
transactivation (7). Further, in vitro studies completed on GFP-tagged AR LBD-deletion mutants
show those receptors still were capable of nuclear trafficking, revealing the importance of the NTD
in nucleocytoplasmic shuffling (8).
The DNA-binding domain (DBD) immediately follows the NTD and serves to bind target
sequences on the DNA, termed hormone response elements (HREs). This is the most conserved
region among the SHRs and serves as the signature domain of this subfamily (9). The DBD is
coded by exons 2 and 3 and contains two zinc fingers allowing the androgen receptor to bind the
major groove of DNA (3, 9). The first zinc finger is responsible for coordinating the gene-specific
nucleotide contacts on the DNA through the use of a conserved P-box motif. The second zinc
finger permits receptor homodimer formation by way of a D-box motif that allows DBD/DBD
contacts between receptors (2).
Although the hinge region of AR is a short sequence composed of roughly 50 amino acids,
it plays dual roles in receptor localization as well as co-activator recruitment (10). The hinge region
is coded by a portion of exon 4 and contains part of a shared nuclear localization signal with the
DBD and LBD of AR (2, 3). Filamin-A, a cytoskeletal protein, interacts with the hinge, DBD, and
LBD of AR and thus enables nuclear import of the receptor (2). This region is also known to
contain an acetylation motif that allows for the modification of lysine residues. Acetylation at these
residues results in co-activator or co-repressor binding, affecting the outcome of DNA
transcription (11).
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The LBD of the androgen receptor is coded by exons 4-8 and forms a 12 α-helical structure
(3, 12). This region is highly selective and demonstrates high affinity for the receptor’s ligands,
testosterone and dihydrotestosterone, and therefore plays an important role in the androgen
receptor signaling axis (3, 12). Upon binding ligand, a nuclear localization signal in the LBD is
exposed and allows nuclear shuttling of the receptor. However, to successfully activate the
transcription of target genes, the AR LBD contains the second activation function site, AF-2, which
interacts with short α-helical peptides containing an LxxLL motif (2, 13–15). In comparison to
AF-1, the AF-2 is highly conserved and consists of amino acids that form a binding pocket on the
surface of the receptor LBD (16). Binding of co-regulators at the AF-2 surface is known to be
influenced by another regulatory surface found in the LBD, binding function 3 (BF3) (13). The
BF3 surface is a hydrophobic cleft in the LBD and binding at this surface has been shown to
allosterically affect the conformation of AF-2 (13). Although each domain of the AR has the
potential to serve as therapeutic targets for the treatment of prostate cancer, as of late the LBD has
been the most thoroughly studied.

1.1.1 Allosteric Relationship Between Androgen Receptor Binding Function 3 (BF3) and
Activation Function 2 (AF-2) Surfaces
To be able to fully exert its functions as a transcription factor, AR activation must occur
through the binding of hormone at the LBD. Upon binding hormone, conformational changes
occur in the LBD that result in co-activator binding at the AF-2 surface. Through the use of small
molecule inhibitors targeted against the AR BF3, a recent study found that blocking this surface
on the LBD of AR influences co-activator recruitment to the nearby AF-2 surface, hinting at the
possibility of an allosteric relationship between these two surfaces (13, 17, 18). Further, it was also
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recently discovered that a novel nuclear receptor binding motif regulates AR activity through
binding the BF3 surface (18). This motif has been found in the co-chaperones FKBP52, Bag-1L,
and SGTα (19).

1.1.2 Classical Androgen Receptor Signaling
The androgenic steroids, testosterone and dihydrotestosterone, are the major androgens that
regulate AR activity. Testosterone is primarily produced by the testes in males; however, it is
converted into dihydrotestosterone (DHT) in the prostate by the enzyme 5α-reductase (2, 3). While
both testosterone and DHT are capable of binding to and activating AR, DHT has a considerably
higher affinity for AR and as a result is able to activate the receptor at lower concentrations. In the
absence of hormone, AR is inactive in the cytoplasm and bound to chaperone proteins such as
Hsp90. Binding of androgen results in the dissociation of chaperone proteins and reveals a nuclear
localization signal (NLS) in the receptor (20). Two nuclear localization signals have been found
in AR: NL1 is found in the DBD and hinge region, and NL2 is found in LBD. NL1 is a bipartite
lysine-rich NLS while NL2 does not have a defined sequence and is only active when the DBD is
bound to androgen (8). Androgen binding also initiates an intramolecular NTD-LBD interaction,
allowing the AR to rapidly convert to an active form by forming a hetero or homo dimer (16). The
hormone-bound AR dimer can now translocate into the nucleus, where it can bind its respective
HREs at promoter and enhancer regions on the DNA, interact with various transcriptional coregulators, and thus regulate gene expression.
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Figure 1.1.1: Modular Structure of the Androgen Receptor

The androgen receptor is composed of 8 exons and organized into 4 distinct domains: The NH2
domain (NTD), the DNA-binding domain (DBD), a small hinge region, and the COOH-terminal
ligand-binding domain (LBD). The NTD contains the first activation function site (AF-1), which
contains a WxxLF motif necessary for optimal transactivation of target genes. The DBD utilizes
two zinc fingers to bind the major groove of DNA. The hinge region grants the receptor structural
flexibility, aids in AR co-activator recruitment, and supports nucleocytoplasmic shuttling through
the use of a shared NLS with the DBD and LBD. The LBD binds the androgens testosterone and
dihydrotestosterone and therefore plays a critical role in receptor activation. This region also
contains the second activation function site, AF-2, a well-characterized binding site of AR coactivators and a site known to be allosterically regulated by the BF3 surface, also found in the
LBD.
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Figure 1.1.2: Androgen Receptor Binding on Hormone Response Elements

The DNA binding domain (DBD) on the androgen receptor contains 2 zinc finger domains that
bind the major groove on hormone response elements (HREs) on the DNA once the receptor has
translocated into the nucleus. Each zinc finger is stabilized by 4 cysteine residues. The first zinc
finger contains a conserved P-box motif that coordinates gene-specific nucleotide contacts on the
DNA. The second zinc finger permits receptor homodimer formation by way of a D-box motif that
allows DBD/DBD contacts between receptors.
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Figure 1.1.3: Androgen Receptor Ligand Binding Domain

The androgen receptor is a ligand-inducible transcription factor and proper regulation of gene
transcription occurs through the ligand binding domain (LBD). The LBD is responsible for binding
the androgens testosterone and dihydrotestosterone, which induces a conformational change in the
receptor, exposing a nuclear localization signal. The LBD also regulates AR co-activator
recruitment due to its activation function 2 (AF-2) and binding function 3 (BF3) sites. The BF3
site is a small, hydrophobic pocket and binding of molecules at this site is known to allosterically
affect the conformation of the AF-2, a site well known to facilitate the binding of AR co-activators.
The presence of two distinct co-regulator binding sites in the AR LBD reveals the complex and
tightly controlled mechanisms in store to regulate AR function.
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Figure modified from: Estébanez-Perpiñá E., Fletterick R.J. (2009) The Androgen Receptor
Coactivator-Binding Interface. In: Mohler J., Tindall D. (eds) Androgen Action in Prostate Cancer.
Springer, New York, NY.
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Figure 1.1.4: Classical Androgen Receptor Signaling

In the absence of hormone, AR is cytosolic and bound to chaperone proteins which maintain the
receptor in an inactive state. When testosterone enters the prostate, it is converted into
dihydrotestosterone by 5α-reductase, the high affinity ligand for AR. Hormone binding of the
receptor releases the bound chaperone proteins and enables the receptor dimerization and
translocation into the nucleus. Upon entering the nucleus, AR recognizes hormone response
elements on the DNA where it will bind to and recruit co-activators of transcription on the
promoter and enhancer regions of the target gene. The transcription activation complex results in
chromatin remodeling and subsequent transcription of AR-regulated genes.
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1.2 THE ROLE OF CHAPERONES IN REGULATING ANDROGEN RECEPTOR MATURATION
The androgen receptor (AR) is a ligand-dependent transcription factor that belongs to the
nuclear receptor superfamily's class 1 subgroup. Members of this superfamily also include steroid
hormone receptors such as the progesterone receptor (PR), glucocorticoid receptor (GR), and
mineralocorticoid receptor (MR) each of which play diverse roles in cell differentiation,
proliferation, and metabolism (4). These receptors share functional similarities as well as a
common protein structure: a variable and unconserved N-terminal domain (NTD), a DNA-binding
domain (DBD), a small hinge region, and a ligand-binding domain (LBD) (21). Although largely
cytosolic, nuclear translocation of AR occurs upon binding androgen, where the DBD recognizes
and binds to hormone-response elements on the DNA to stimulate transcription of target genes.
This complex signaling axis plays a large role in regulating androgen receptor activity and recent
studies have suggested that abnormal chaperone expression could lead to aberrant AR signaling,
resulting in the initiation and development of prostate cancer (21).
Originally discovered through their role in cellular response to stress, chaperone proteins
have been well characterized to aid in the folding of steroid hormone receptors even in the absence
of cell stress. By recognizing and binding to hydrophobic regions on partially folded proteins,
chaperones encourage cycles of chaperone-mediated folding thereby preventing their client
protein’s irreversible aggregation and subsequent degradation (21). As mentioned previously,
ligand-free AR is found in the cytoplasm in an inactive but highly responsive state bound at the
LBD by a heteromeric complex composed of heat-shock proteins (Hsp), co-chaperones, and
tetratricopeptide repeat (TPR) containing proteins (21, 22). Due to its ligand-inducible activation,
AR is required to be in constant association with chaperones and co-chaperones to reach
maturation (22). This molecular complex is believed to maintain the AR LBD in a stable, partially
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unfolded intermediate complex with high affinity for androgen. Once hormone binds, the receptorchaperone complex dissociates, freeing the receptor for nuclear trafficking (21). This chaperonemediated regulatory mechanism of AR highlights the role of molecular chaperones as important
players in the events prior to and downstream of receptor activation as well as throughout the life
cycle of AR (21).
In order to achieve its high affinity ligand-binding conformation, AR must undergo a
carefully regulated cycle mediated by various chaperones and co-chaperones. This cycle requires
no less than twelve proteins forming at least three distinct receptor complexes (early, intermediate,
and mature) with each complex composed of distinct chaperone and co-chaperone proteins. The
minimal complex required for efficient folding consists of: heat-shock protein 70 (Hsp70), heatshock protein 40 (Hsp40), Hsp organizing protein (Hop), heat-shock protein 90 (Hsp90), and p23
(21, 22). Briefly, SHRs are initially bound by Hsp70 which then transfers the receptor to Hsp90
via Hop. The receptor-Hsp90 complex is stabilized by the addition of p23, Hop dissociates from
the complex allowing the binding of TPR proteins to occur, resulting in a mature receptor capable
of binding hormone (23). While chaperones and co-chaperones are recruited in a seemingly
organized and step-wise manner, it is important to note that this cycle is a highly dynamic process
with chaperones and co-chaperones continuously fluctuating between binding and being released
from each complex.
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1.2.1 Early Complex
Although much detail is not yet known about what happens when SHRs emerge from the
ribosome, the first chaperone believed to interact with AR is Hsp70 along with its co-chaperone
Hsp40 (21). Hsp40 is a J-domain containing co-chaperone which stimulates Hsp70 ATP-ase
activity upon binding, resulting in a conformational change in the complex that results in a tighter
association between Hsp70 and the SHR (22, 23). Hsp40 is believed to facilitate the proper
alignment of the interaction surfaces between the receptor and Hsp70. This event is crucial in
priming the SHR for a second ATP-dependent interaction with Hsp90 in the intermediate complex
(21, 22). At this stage in the chaperoning pathway, the early complex is also responsible for
conducting protein surveillance in eukaryotic cells and thus marking improperly folded SHRs for
degradation via the ubiquitin/proteasome pathway (22).

1.2.2 CHIP-mediated Degradation
If the receptor is unable to complete the chaperone cycle, it must undergo degradation to
prevent protein accumulation. To successfully transition its function from protein folding to
promoting protein degradation, the early complex recruits a TPR-containing co-chaperone termed
carboxyl terminus of Hsp70-interacting protein (CHIP). CHIP plays an integral role in this shift of
the chaperone cycle by binding Hsp70 and confining the chaperone to an ATP-bound state, thereby
inhibiting the folding activity of the chaperone (21)(22). CHIP also functions as an E3 ubiquitin
ligase and promotes ubiquitination of chaperone substrates through stochastic sampling of
chaperone-bound substrate complexes. Recent biochemical studies have suggested that CHIP is
capable of randomly sampling client proteins in the chaperone cycle to facilitate the degradation
of erroneously folded SHRs (24). In addition, another co-chaperone termed Bcl-2-associated
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athanogene 1 (Bag-1) uses a C-terminal domain to bind Hsp70 while its N-terminus serves as a
physical link between Hsp70 and the proteasome, making Bag-1 responsible for releasing the
client protein into the proteasome. Therefore, target protein degradation is successfully completed
by the cooperation of two co-chaperones: CHIP mediates ubiquitin attachment to the target protein
while Bag-1 directs the protein to the proteasome (22).

1.2.3 Intermediate Complex
If SHRs are successful in the early complex, they are allowed to progress into the
intermediate complex. Hsp70-interacting protein (Hip) initiates the formation of this stage by
utilizing its N-terminal TPR domain to interact with Hsp70. This interaction keeps Hsp70 bound
to ADP, forming an Hsp70/SHR complex bound together with high affinity. Another cochaperone, Hsp70/90 organizing protein (Hop), is also found in the intermediate complex. Hop
binding to the complex recruits an Hsp90 homodimer and functions as a scaffold protein between
Hsp70 and Hsp90 to facilitate the SHR transfer from Hsp70 to Hsp90 (21). Hop has also been
shown to stabilize the Hsp90 dimer formed during this stage by utilizing a conserved TPR clamp
domain. With Hop bound to the TPR acceptor site in the C-terminus of Hsp90, steric hindrance
introduced at this site prevents other proteins from binding the TPR-acceptor site on Hsp90 (22).
Interactions between Hsp90 and TPR proteins are highly conserved throughout lower and
higher eukaryotes. Other TPR containing co-chaperones that might bind the TPR acceptor site on
Hsp90 are: CHIP, Hip, FKBP51/52, Cyp40, and SGTα (22). FKBP51, FKBP52, and Cyp40 are
also known as the large immunophilins due the presence of a peptidyl prolyl isomerase (PPIase)
domain in addition to their TPR domains (23). Hsp90 has two TPR acceptor sites: the canonical
site is found in the C-terminus and a novel site in the N-terminus has recently been discovered
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(25). Until recently, it was believed that the primary function of the N-terminal site is to bind
ATP, allowing for the interaction of the two N-terminal domains of Hsp90 in the dimer (22).
However, it has recently been found that this site can also function as an additional interaction site
for TPR-containing co-chaperones, with preference for those containing a PPI-ase domain such as
the immunophilins FKBP51 and FKBP52 (26–28). One TPR-containing co-chaperone with a
PPIase domain known to bind this acceptor site on Hsp90 is GCUNC-45. Once GCUNC-45 is
bound to this domain, it maintains the SHR in the intermediate complex to allow for additional
chaperone events to occur before moving into the mature complex. This stalled checkpoint can be
reversed in the presence of FKBP52, which instead promotes SHR entry into the mature complex
by displacing GCUNC-45 through competitive binding. The presence of two TPR acceptor sites
on Hsp90 with varying specificity provide another means of flexibility and control in regulating
the SHR chaperoning pathway (22).
Small glutamine-rich tetratricopeptide repeat-containing alpha (SGTα) is a co-chaperone
that contains a C-terminal TPR domain, which it uses to directly interact with Hsp70 and very
weakly with Hsp90. SGTα lacks a PPIase domain, which is unusual for related TPR-containing
proteins. SGTα interaction with Hsp70 enhances Hsp70’s affinity to the client protein by favoring
the ADP-bound conformation of the chaperone/client intermediate complex (29–31). SGTα binds
to the hinge region of AR, blocking its ability to translocate into the nucleus. However, the
presence of DHT induces SGTα dissociation from the hinge region, allowing AR nuclear
translocation and subsequent activation of target genes (22). It has recently been reported that
overexpression of SGTα suppresses SHR activity, while deletion has been shown to enhance
receptor activity (30). These observations suggest a quality control role of SGTα in the
intermediate complex: upon entry into the intermediate complex SGTα interacts with the hinge
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region of the receptor while binding to Hsp70 via its TPR domain, forming the intermediate
complex composed of Hsp70, Hsp90, Hop, the receptor, and SGTα (22).

1.2.4 Mature Complex
Progression into the mature complex is initiated when Hsp90 regains its ATPase activity,
which is suppressed during the intermediate complex. This allows ATP to bind, inducing a
conformational change in the Hsp90 dimer that results in the N-terminal domains of the Hsp90
dimers to come into contact with one another. These structural changes allow Hop and Hsp70 to
be released while simultaneously recruiting p23 into the complex (23). This permits for the
addition of one of the TPR-containing co-chaperones (such as FKBP52) into the complex. p23
plays an important role in the mature complex since it is a conformation-specific binding protein,
meaning that p23 will only bind to the dimerized Hsp90 conformation specific to the mature
complex (22, 23). It also facilitates the maturation of the client SHR by stabilizing the newly closed
conformation of Hsp90. It is in this mature complex containing Hsp90, p23, a TPR-containing
PPIase co-chaperone, and the SHR that the receptor has reached a high affinity ligand binding
conformation. This mature complex remains cytosolic until the presence of ligand. Ligand binding
stimulates release of the SHR from the mature complex, the SHR dimerizes, allowing it to
translocate into the nucleus, and bind hormone response elements to stimulate transcription of
target genes where the receptor can mediate various physiological functions such as development,
differentiation, metabolic processes, and reproduction. Although it is generally believed that ligand
binding releases the SHR from the mature chaperone complex, studies have shown that SHRs are
capable of cycling through this dynamic cycle of chaperones while being bound to ligand (22).
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Once this cycle of folding and nuclear translocation is completed, receptors can re-enter the
chaperoning process beginning with Hsp40 and Hsp70 (22).
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Figure 1.2.1: Chaperone Mediated Assembly of Steroid Hormone Receptors.

The nascent steroid hormone receptor polypeptide enters the chaperone pathway when Hsp40
binds and recruits Hsp70, forming the early chaperone complex in the cytosol. At this junction in
the cycle, the receptor can continue forth into the intermediate complex or be degraded via the
CHIP-mediated pathway. For proper proteasomal degradation to occur, CHIP ubiquitinates the
misfolded receptor while BAG-1 serves as a physical link between the target protein and the
proteasome. Intermediate complex formation occurs when Hip binds Hsp70, forming a tighter
association between Hsp70 and the receptor. Hop then binds both Hsp70 and Hsp90 via its two
TPR domains, allowing Hop to serve as a bridge between the two chaperones, enabling the SHR
transfer from Hsp70 onto Hsp90. Binding of ATP to the Hsp90 homodimers leads to
conformational changes that induces the release of Hsp70, Hop, and Hip. The 23-kDa cochaperone p23 is recruited to stabilize the Hsp90-SHR complex, forming the final mature complex.
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The SHR will remain cytosolic and bound to this chaperone complex until the presence of
hormone. Upon binding hormone, the chaperone complex disassembles and the receptor is
imported into the nucleus, where it can then activate transcription of target genes.
Figure from: Naihsuan C. Guy, Yenni A. Garcia and Marc B. Cox, “Therapeutic Targeting of the
FKBP52 Co-Chaperone in Steroid Hormone Receptor-Regulated Physiology and Disease”,
Current Molecular Pharmacology (2016) 9: 109.
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1.3 THE ROLE OF THE FKBP52 COCHAPERONE
As mentioned above, before the receptor can reach a hormone binding conformation, the
receptor must undergo a chaperone-mediated folding process. The final complex that results in a
mature receptor is composed of: Hsp90, p23, and FKBP52. FKBP52 is a known specific positive
regulator of AR, GR, and PR and is known to regulate hormone binding and nuclear translocation
(32, 33). By way of a C-terminal TPR domain, FKBP52 associates with receptor-Hsp90 complexes
which then results in the enhancement of receptor hormone binding (34). Recent evidence has
revealed that FKBP52 protein expression is elevated in patients diagnosed with CRPC as compared
to those with hormone-dependent prostate cancer. Further, elevated FKBP52 expression in CRPC
patients has been associated with poor survival outcome (35).
FKBP52 is composed of an N-terminal proline-rich loop, a peptidyl-prolyl cis-trans
isomerase (PPI-ase) catalytic pocket, an FK1 region connected to an FK2 region via an FK linker
domain, and a C-terminal tetratricopeptide repeat domain (TPR). FKBP52 shares roughly 70%
sequence similarity with FKBP51 and the two proteins are also structurally similar, however only
FKBP52 positively influences receptor activity. By exploiting these sequence similarities between
FKBP51 and FKBP52, functional domain mapping studies have demonstrated that the proline-rich
loop overhanging the PPI-ase catalytic pocket is critical for FKBP52 to exert its function on the
steroid hormone receptors (36–38). Given the critical role of FKBP52 in AR signaling both in vitro
and in vivo, it has emerged as an attractive target for the treatment of prostate cancer.
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1.4 THE ROLE OF ß-CATENIN IN REGULATING THE ANDROGEN RECEPTOR
1.4.1 β-catenin in the Wnt Signaling Pathway
In a homeostatic environment, the Wnt signaling pathway is critical for gene expression,
cell cycle control, and cell-to-cell adhesion (39, 40). β-catenin is the principal agent in the Wnt
signaling pathway and, through the use of multiple protein-protein contacts, plays important
cellular roles in cell adhesion from embryogenesis through tumorigenesis (41). The structure of βcatenin is organized into 3 components: a central association region termed the armadillo repeat
region (ARM) flanked by an unstructured NH2 domain and a COOH domain (42, 43). In the cell,
β-catenin can be found in adherens junctions, in the cytosol, or in the nucleus and most protein
contacts with β-catenin are conducted through the ARM region (39). Canonical Wnt signaling
occurs when Wnt ligands bind their respective transmembrane receptors resulting in a series of
downstream phosphorylation events that allow for the accumulation of intracellular β-catenin. This
event triggers β-catenin movement into the nucleus where it binds T-cell factor (Tcf) and is then
able to bind target DNA sequences (39). A degradation complex consisting of glycogen synthase
kinase 3 (GSK3), casein kinase 1α (CK1α), axin, and APC regulate intracellular β-catenin levels
(40). To maintain proper control of β-catenin expression levels and transcriptional activation of βcatenin target genes, phosphorylation of β-catenin by the degradation complex mentioned above
results in ubiquitination and proteasomal degradation while cytosolic ligands of β-catenin block
the degradation complex, allowing β-catenin activation of genes (40).
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1.4.2 β-catenin’s Functional Role with the Androgen Receptor
Of the SHRs, β-catenin has only been found to selectively bind AR and is well known to
be a regulator of AR-mediated transcription, making it an attractive therapeutic target for the
treatment of prostate cancer (39). Similar to other proteins known to interact with AR, β-catenin
contains an LxxLL motif however the leucine residues are buried deep within the hydrophobic
core of the armadillo repeats, making the motif inaccessible to AR (44). Further, mutational studies
have revealed that disruption of the LxxLL motif in β-catenin does not affect its ability to bind
AR. Recent co-crystal structural analysis of β-catenin bound to another nuclear receptor, the liver
receptor homolog-1 (LRH-1), have revealed that β-catenin is binding the ligand binding domain
of LRH-1 at a surface that is functionally distinct from the AF-2 transactivation domain (42). Given
the highly conserved structure of the LBD between members of the nuclear receptor superfamily,
these results have been translated to the ligand binding domain of the androgen receptor and have
revealed that mutating the following residues on β-catenin affected not only binding of β-catenin
to LRH-1 but also binding of β-catenin to AR: Y306, K345, W383 (42).
β-catenin directly binds AR to stimulate production of AR mediated genes, and most
importantly, the AR gene itself is a transcriptional target of β-catenin (39, 45). Mutations that result
in stable and persistent β-catenin expression have been shown to cause increased levels of βcatenin in the nucleus, resulting in increased AR transcriptional activity. The interaction between
β-catenin and AR has been found to be ligand sensitive, with increased binding in the presence of
the ligand DHT (46). Ligand-bound AR competes with TCF4 for regulation by β-catenin (47). The
clinical relevance of AR regulation by β-catenin has recently gained significance since studies
have found that β-catenin/AR signaling may be increased in the hormone refractory state of
prostate cancer (39, 48). Further, yeast-two hybrid studies coupled with expression of AR deletion
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mutants in mammalian cell lines have found that the LBD of AR sufficient for interaction with βcatenin (49).

1.4.3 FKBP52 and β-catenin Act in Concert to Promote Androgen Receptor Function
Given this information, our lab recently explored the possibility of a relationship between
FKBP52, β-catenin, and AR. The results from these studies were the first to demonstrate that
FKBP52 and β-catenin interact directly to promote a synergistic up-regulation of both hormonedependent and hormone-independent AR signaling (32). Further, our lab also found that FKBP52
promotes β-catenin’s interaction with AR and FKBP52 is required in order for β-catenin to upregulate AR activity in prostate cancer cells (32). Because β-catenin is predicted to bind the BF3
surface on AR, it follows that blocking access to this site should reduce β-catenin-induced receptor
potentiation. Through the use of a small-molecule inhibitor termed MJC13, which targets the AR
BF3 surface, our lab was able to validate that blocking this surface disrupts receptor potentiation,
suggesting that the β-catenin and FKBP52 interaction is occurring here.
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Figure 1.4.1: Structure of β-catenin

β-catenin is composed of an unstructured NH2, an armadillo repeat domain, and a carboxyl
terminal domain. The armadillo repeat region (ARM) is where the majority of protein contacts
with β-catenin occur. This region spans 12 domains each composed of 3 α-helices. The orphan
nuclear receptor LRH-1 has been shown to bind ARM 3-9 while the androgen receptor has been
shown to require ARM 5 and 6.
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Figure 1.4.2: Structure of β-catenin Bound to the Orphan Nuclear Receptor LRH-1

As determined by Yumoto et al, β-catenin binds the ligand binding domain of LRH-1 using the
amino acid residues Y306, K345, W383. Due to the high structural similarities between nuclear
receptors, it is predicted that β-catenin also binds the ligand binding domain of the androgen
receptor, shown at right, at a region that likely overlaps the BF3 surface.
Figure from: Yumoto F. et. al. (2012) Structural basis of coactivation of liver receptor homolog-1
by β -catenin. Proc Natl Acad Sci U S A 109: 143-148
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1.5 PROSTATE CANCER MECHANISM OF ACTION
Prostate cancer is the most common non-cutaneous cancer in men and the second leading
cause of cancer-related deaths in men in the United States (2, 3). According to the American
Cancer Society, new cases of prostate cancer for the year 2021 are projected to total 248,530 of
which 34,130 are estimated to be fatal. Initiation and progression of prostate cancer are
distinctively dependent on the androgen receptor and, based on AR’s response to hormone, can be
divided into two stages: early stage and late-stage (50, 51). During the early-stage, AR relies on
the presence of hormone (DHT) to translocate into the nucleus and stimulate production of target
genes, thereby driving tumor growth (50, 52). Initial treatments for early-stage prostate cancer
exploit the receptor’s dependency on hormone by using androgen deprivation to reduce tumor
growth (53). While initial responses to these treatments are favorable, tumors invariably occur and
patients progress into the lethal late-stage, termed castration resistant prostate cancer (CRPC), for
which there is currently no treatment (2, 54). During CRPC, various AR signaling pathways
become disrupted which lead to AR no longer requiring hormone for nuclear translocation. This
enables the recurrence of tumors and eventually the development of metastatic disease.
Current therapeutic strategies for the treatment of prostate cancer are focused on preventing
its nuclear localization using anti-androgens that compete with hormone or targeting the NH2
domain of the receptor. However, these techniques have been met with limited success due to the
receptor’s eventual resistance to anti-androgens and its poorly conserved NH2 domain. Since the
late 1990’s, Hsp90 inhibitors have also been explored as potential therapies, but due to their
ubiquitous state, target specificity has been difficult to accomplish. Current novel techniques have
begun to consider other AR functional domains with a goal to affect co-activator binding to the
receptor (55). One of these targets is the AR BF3 surface. Recently, studies have suggested that
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binding of targeted small molecules to this site are capable of inhibiting co-activator binding to
the receptor, thereby preventing its nuclear import. The AR BF3 surface has proven to be a
promising target for regulating the androgen receptor signaling pathway and more studies must be
conducted to elucidate the mechanisms behind its functioning.

1.6 DISSERTATION RESEARCH FOCUS AND HYPOTHESIS
This project aims to assess the various proteins which play a role in regulating AR activity,
with a central focus on the FKBP52 cochaperone. FKBP52 has emerged over the years as an
attractive therapeutic target for the treatment of prostate cancer, due to its ability to positively
regulate the AR at a site found on the hormone binding domain. The FKBP52 cochaperone is a
critical factor in steroid hormone receptor folding and maturation and we would like to further
understand the influence this cochaperone has on regulating androgen-dependent transcriptional
programs. Therefore, the goal of this dissertation is to better understand the significance of
FKBP52 in regulating AR activity, in an effort to improve therapeutic targeting this cochaperone.
These goals were addressed through the following approaches:
1.

Assess amino acid residues on FKBP52 needed to regulate AR activity and identify
novel cochaperones that function in a manner similar to FKBP52.

2.

Examine the downstream effects of AR DNA binding and gene expression when
the FKBP52 gene is knocked out of prostate cancer cells.

3.

Validate FKBP52 as a therapeutic target for inhibiting AR activity.
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Chapter 2: Functional Characterization of FKBP52 and β-catenin Interactions with the
Androgen Receptor
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2.1 SUB

AIM

1: ASSESS

THE DOMAIN AND FUNCTIONAL REQUIREMENTS FOR

FKBP52

AND ß-

CATENIN TO MEDIATE ANDROGEN RECEPTOR ACTIVITY

2.1.1 Rationale
FKBP52 is an Hsp90 cochaperone that is known to positively regulate androgen receptor
activity and is required for the development of androgen-dependent tissues (33, 36–38, 56).
Although FKBP52 harbors catalytic activity, previous studies have shown that the proline-rich
loop overhanging the catalytic pocket, and not the catalytic pocket itself, is important for FKBP52regulation of AR (38). β-catenin is well established as a key component of AR-mediated
transcription and predictive modeling studies indicate that β-catenin may be interacting with AR
at the ligand-binding-domain, at a site known as the BF3 surface (42, 46, 49, 57–59). Recently,
our lab has established that FKBP52 and β-catenin interact directly with each other to
synergistically up-regulate AR activity (32). The use of mutagenesis studies and small molecules
directed against the BF3 surface on AR suggest that the FKBP52/β-catenin interactions are
occurring on the AR BF3 surface (60). Indeed, MJC13, an AR-inhibitor developed by our lab,
shows an inhibition of FKBP52-regulated AR signaling in prostate cancer cells (61). However, the
residues required for both FKBP52 and β-catenin to exert their function on the AR have not been
extensively studied. Identification of these critical amino acids on both proteins might better define
the requirements needed to exert influence on AR activity, potentially through the AR BF3 surface.
We hypothesized that by mutating residues on FKBP52 and β-catenin, we would lose interactions
with AR, and therefore observe loss of receptor potentiation. Functional AR-mediated luciferase
assays were conducted along with co-immunoprecipitations to examine protein-protein
interactions. An FKBP52 loss-of-function mutant was generated to resemble the structure of
FKBP51, a cochaperone closely related to FKBP52 but is known to be unable to potentiate AR
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activity, possibly due to differences in the region containing the proline-rich loop (37, 59). Taking
the same approach as with FKBP52, we selected β-catenin mutants based on a study conducted by
Yumoto et al. 2012. These mutants are shown to have lost their ability to bind to the ligand binding
domain of liver receptor homolog-1, a nuclear receptor closely related to the androgen receptor.

2.1.2 Materials and Methods
Constructs
The FKBP52 loss-of-function plasmid was originally created by Yumoto et al. 2012. by
cloning human FKBP52 into the p423GPD yeast expression vector and using site-directed
mutagenesis to introduce the proline to leucine mutation at position 119 (38). Samaniego et al.
2015 regenerated the mutations directly into the pCI-neo mammalian expression vector using the
Quick-Change II site-directed mutagenesis kit (32). The β-catenin mutants were a generous gift
from Robert Fletterick at the University of California, San Francisco.
Cell Culture and Transient Transfection
FKBP52-deficient mouse embryonic fibroblasts (52KO MEF) were maintained at 5% CO2
in Minimal Essential Medium (MEM) in the presence of 10% fetal bovine serum (FBS). For
transfection, cells were seeded into a 6-well plate at a density of 2x105 cells/well and allowed to
reach 80% confluency prior to transfection. Twenty-four hours prior to transfection, cells were
switched to media containing charcoal/dextran treated FBS. Transfection was conducted as
described by Samaniego et al. 2015 with some modifications. Cells were transfected using
Lipofectamine 2000 at a DNA to lipofectamine ratio of 1:3 in MEM lacking FBS according to the
manufacturer’s instructions. Transfections included plasmids for a constitutive β-galactosidase
reporter plasmid as a transfection control, a firefly luciferase reporter plasmid driven by the
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androgen-dependent probasin promoter, a human AR expression plasmid, and plasmids expressing
the indicated FKBP52 or β-catenin wild-type or mutated variants.
Receptor-Mediated Reporter Assays in FKBP52KO MEF Cell Line
Reporter assays were conducted as described by Samaniego et al. 2015 with some
modifications. Single hormone concentrations were previously determined from hormone doseresponse curves. Twenty-four hours following the transfection, cells were dosed with 10pM DHT
or an equal volume of EtOH. After approximately 16 hours of incubation with hormone, cells were
lysed with 100μL mammalian protein extraction reagent (M-PER) supplemented with HALT
protease inhibitor. After clarifying the lysates, AR-mediated luciferase expression was quantified
by mixing 40μL of cell lysate with 100μL of luciferase assay reagent (Promega) in a 96-well plate
and incubated at room temperature for five minutes. β-galactosidase expression was quantified by
adding 20μL cell lysate with 100μL of Tropix Gal-Screen in a 96-well plate at room temperature
for two hours. Quantification of luminescence was conducted in a microplate luminometer with
luminescence measured as Relative Light Units (RLU) and normalized to β-galactosidase activity
(RLU/ β-galactosidase) to control for transfection efficiency.
Statistical Analysis of Reporter Assay Data
All results presented here reflect at least three independent experiments. Statistical analysis
was conducted using GraphPad Prism 8 software. The data were normalized to a percentage of the
maximum luciferase activity and the means assessed by one-way analysis of variance (ANOVA)
followed by pair-wise comparisons using Tukey’s multiple comparisons test. A value of p< 0.05
determined statistically significant values.
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Co-immunoprecipitation
Co-immunoprecipitations were performed from lysates of 52KO MEFs that were cotransfected with plasmids expressing the androgen receptor, the indicated flag-tagged FKBP52 or
β-catenin, and the indicated FKBP52 or β-catenin variants. 52KO MEF cells were maintained in
MEM media supplemented with 10% charcoal/dextran treated FBS and were treated with 10pM
DHT or an equal volume of EtOH following transfection. Cells were lysed with RIPA lysis buffer
supplemented with EDTA-free HALT protease inhibitor. Whole cell lysates were incubated with
magnetic beads conjugated to monoclonal mouse anti-flag antibody overnight at 4°C. Beads were
washed three times with RIPA+HALT at 4°C and elution was completed using 5X-flag peptide
diluted in the wash buffer. Bound proteins were separated by SDS-PAGE then transferred to a
PVDF membrane, and subjected to Western blot analysis with anti- β-catenin, anti-AR, and antiFKBP52.
Western Blot Analysis
Protein concentrations of lysate samples were determined via Bradford Assay using
Coomassie Plus Assay Kit according to the manufacturer’s instructions. Thirty µg of each sample
was loaded into a 10-well 4-12% Bis-Tris protein gel and transferred to a PVDF membrane. The
presence of AR was detected using mouse monoclonal anti-AR antibody (Santa Cruz), β-catenin
using mouse monoclonal anti-β-catenin (Santa Cruz), and FKBP52 using rabbit polyclonal antiFKBP52 (Cell Signaling). All antibodies were alkaline phosphatase conjugated for use with the
Immun-Star AP substrate upon exposure to X-Ray film.

32

2.1.3 Results
The Proline-Rich Loop on FKBP52 may be a Requirement for Receptor Potentiation and
Complex Formation with AR and β-catenin.
FKBP52 shares approximately 70% sequence similarity with its homolog FKBP51,
however it is well known that FKBP52, and not FKBP51, has the ability to potentiate androgen
receptor activity (37, 38). Studies examining the differences in their structure reveal differences at
the proline-rich loop region, an area on FKBP52 that is required for regulation of the androgen
receptor (32, 38). To gain a better understanding of the role the proline-rich loop is playing,
receptor-mediated luciferase assays and co-immunoprecipitations were conducted using a loss-offunction FKBP52 in which a key proline residue, P119, was changed to leucine. In the reporter
assay results, it is evident that the mutant does not potentiate receptor activity as well as wild-type
FKBP52 when combined with β-catenin (Figure 2.1.1). Co-immunoprecipitation results indicate
that proline 119 on wild-type FKBP52 may also be required for complex formation with AR and
β-catenin (Figure 2.1.2).

β-catenin Armadillo Repeat Region May Serve as a Contact Surface for the Androgen Receptor.
β-catenin has been previously established to exhibit strong interactions with AR but not
with other SHRs such as ER, PR, and GR (49). Recently, the cocrystal structure has been reported
of β-catenin in complex with the ligand binding domain of the liver receptor homolog-1 (LRH-1),
an orphan nuclear receptor that shares high structural similarity with the androgen receptor (42).
This study found that the ARM region on β-catenin was crucial for interactions with LRH-1 and
this region was also needed for β-catenin interaction with AR. Here, we’ve taken three of the βcatenin mutants used in the Yumoto et al. 2012 study to examine the role that the ARM region
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may play in AR potentiation and complex formation between β-catenin, FKBP52 and AR. The
three β-catenin mutants used here were Y306A, K345A, and W383A which correspond to ARMs
4, 5, and 6, respectively. We conducted receptor-mediated luciferase assays on each β-catenin
mutant, with and without FKBP52, and can observe a loss of AR potentiation, with the most
significant decrease of AR activity occurring with the W383 mutant (p = 0.006) (Figure 2.1.3).
Co-immunoprecipitations were then conducted using the W383 mutant using a flag-tagged
FKBP52, which revealed failure of complex formation with FKBP52 and AR (Figure 2.1.4).

34

Figure 2.1.1 The FKBP52-P119L Loss-of-Function Mutant Exhibits Reduced Receptor
Potentiation, Indicating the Importance of the Proline-Rich Loop.

Wild-type AR, the AR-inducible luciferase reporter plasmid, and the constitutively active βgalactosidase reporter plasmid were co-transfected simultaneously with each of the plasmids
indicated for the different treatment groups in 52KO MEF cells. Cells were induced with 10pM
DHT. Following cell lysis, AR expression was tested through a receptor-mediated luciferase assay,
followed by normalization to β-galactosidase activity. Asterisks denote statistically significant
differences as compared to the vector alone control (***p < 0.005; ****p < 0.0001). Androgen
receptor potentiation is significantly less in the FKBP52-P119L mutant as compared to wild-type
FKBP52 when combined with β-catenin (p < 0.05).
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Figure 2.1.2 The FKBP52 Loss-of-Function Mutant Fails to Form Complex with AR and βcatenin.

A co-immunoprecipitation to assess the ability of the FKBP52 loss-of-function mutant to form a
complex with AR and β-catenin, without DHT in 52KO MEF cells. Cells were co-transfected with
flag-tagged β-catenin, wild-type AR, and either wild-type FKBP52 or the mutated FKBP52P119L. Blots were probed for β-catenin, AR and FKBP52. Inputs shown at bottom. All lanes were
loaded with equal amounts of protein.
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Figure 2.1.3 Mutations On β-catenin Reveal Novel Residues Needed to Synergize with FKBP52
to Potentiate AR Activity.

Mutations on ARM-5 and 6 of β-catenin show reduced AR potentiation in 52KO MEF cells. Wildtype AR, the AR-inducible luciferase reporter plasmid, and the constitutively active βgalactosidase reporter plasmid were co-transfected simultaneously with each of the plasmids
indicated for the different treatment groups in 52KO MEF cells. Cells were induced with 10pM
DHT. Following cell lysis, AR expression was tested through a luciferase assay, followed by
normalization to β-galactosidase activity. Asterisks denote statistically significant differences as
compared to the vector alone control (***p < 0.005; ****p < 0.0005). When combined with
FKBP52, β-catenin W383A does not potentiate receptor activity as well as the wild-type β-catenin
and FKBP52 combination (p = 0.0094).
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Figure 2.1.4 β-catenin W383A Fails to Form Complex with AR and FKBP52.

A co-immunoprecipitation to assess the ability of β-catenin W383A to form the canonical complex
with AR and FKBP52. 52KO MEF cells were co-transfected with flag-tagged FKBP52, AR, and
either wild-type β-catenin or β-catenin W383A. Cells were induced with 10pM DHT. Blots were
probed for FKBP52, AR, and β-catenin. Inputs shown at bottom. All lanes were loaded with equal
amounts of protein.
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2.2 SUB AIM 2: IDENTIFICATION OF THE COCHAPERONE BAG-1L AS A NOVEL INTERACTOR IN
THE AR/ß-CATENIN COMPLEX

2.2.1 Rationale
Bag-1L (Bcl-2-associated athanogene) is an Hsp70 cochaperone belonging to a large
family of proteins which are defined by containing the conserved Bag domain (62). In humans,
there are four Bag-1 isoforms each deriving from a single mRNA possessing alternative translation
initiation sites: Bag-1L, Bag-1M, Bag-1, and Bag-1S (62). The synthesis of Bag-1L begins at an
upstream CUG codon, while the other three Bag-1 proteins begin translation at the AUG codon
(62, 63). This difference in the N-terminal sequence of Bag-1L is believed to contribute to its
distinct function when compared to the other three Bag-1 proteins since a nuclear localization
signal is found in the N-terminus, making the subcellular location of Bag-1L primarily nuclear
(63, 64). Each of the four human Bag-1 isoforms have been found to regulate the activity of several
nuclear receptors, however only the long form (Bag-1L) has been closely linked to the AR. Recent
studies have determined that the presence of a duplicated GARRPR motif in the N-terminus of
Bag-1L is responsible for this AR-specificity (63, 65). This motif, unique to Bag-1L and not found
on other AR regulatory proteins, interacts with the C-terminal BF3 domain of AR while the Bag
domain interacts with the N-terminus of AR, resulting in enhanced receptor transactivation
potentially via the AR ligand binding domain (63). Because of this unique mechanism of
regulation on the AR, Bag-1L has very recently become an attractive therapeutic target for the
treatment of CRPC. Indeed, the use of small molecules directed against the BF3 surface of AR
result in the loss of Bag-1L interaction at that site (19). Previous studies have shown that the Bag
proteins do indeed interact with β-catenin (60, 63, 66). However, the question remains whether
Bag-1L is interacting with AR in the context of the AR/β-catenin complex. Due to its ability to
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interact with β-catenin and the AR BF3, we hypothesized that Bag-1L would function in a manner
similar to FKBP52 and would synergize with β-catenin to enhance AR activity in vitro. Functional
AR-mediated luciferase assays were conducted in the 22Rv1 prostate cancer cell line in parallel
with co-immunoprecipitations to examine protein-protein interactions.

2.2.2 Materials and Methods
22Rv1 Cell Culture and Transient Transfection
The 22Rv1 prostate cancer cell line was maintained at 5% CO2 in RPMI 1640 growth media
in the presence of 10% fetal bovine serum (FBS). Twenty-four hours prior to transfection, cells
were switched to media containing charcoal/dextran treated FBS. Transfection was conducted as
described by Samaniego et al. 2015 with some modifications. Cells were seeded into a 6-well plate
at a density of 2x105 cells/well and allowed to reach 80% confluency prior to transfection. Cells
were transfected using Lipofectamine 2000 at a DNA to lipofectamine ratio of 1:3 in RPMI lacking
FBS according to the manufacturer’s instructions. Transfections included plasmids for a
constitutive β-galactosidase reporter plasmid as a transfection control, a firefly luciferase reporter
plasmid driven by the androgen-dependent probasin promoter, a human AR expression plasmid, a
human β-catenin expression plasmid, and a plasmid expressing human Bag-1L.
Receptor-Mediated Reporter Assays in 22Rv1 Prostate Cancer Cells
Reporter assays were conducted as described by Samaniego et al. 2015 with some
modifications. Single hormone concentrations were previously determined from hormone doseresponse curves. Twenty-four hours following transfection, cells were dosed with 10nM DHT or
an equal volume of EtOH. After approximately 16 hours of incubation with hormone, cells were
lysed with 100μL mammalian protein extraction reagent (M-PER) supplemented with HALT
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protease inhibitor. After clarifying the lysates, AR-mediated luciferase expression was quantified
by mixing 40μL of cell lysate with 100μL of luciferase assay reagent (Promega) in a 96-well plate
and incubated at room temperature for five minutes. β-galactosidase expression was quantified by
adding 20μL cell lysate with 100μL of Tropix Gal-Screen in a 96-well plate at room temperature
for two hours. Quantification of luminescence was conducted in a microplate luminometer with
luminescence measured as Relative Light Units (RLU) and normalized to β-galactosidase activity
(RLU/ β-galactosidase) to control for transfection efficiency.
Statistical Analysis of Reporter Assay Data
All results presented here reflect at least three independent experiments. Statistical analysis
was conducted using GraphPad Prism 8 software. The data were normalized to a percentage of the
maximum luciferase activity and the means assessed by one-way analysis of variance (ANOVA)
followed by pair-wise comparisons using Tukey’s multiple comparisons test. A value of p < 0.05
determined statistically significant values.
Co-immunoprecipitation
Co-immunoprecipitations were performed from 22Rv1 cell lysates that were co-transfected
with plasmids expressing flag-tagged β-catenin, androgen receptor, and Bag-1L. 22Rv1 cells were
maintained in RPMI media supplemented with 10% charcoal/dextran treated FBS and were treated
with 10nM DHT or an equal volume of EtOH following transfection. Cells were lysed with RIPA
buffer supplemented with EDTA-free HALT protease inhibitor. Whole cell lysates were incubated
with magnetic beads conjugated to monoclonal mouse anti-flag antibody overnight at 4°C. Beads
were washed three times with RIPA+HALT at 4°C and elution was completed using 5X-flag
peptide diluted in the wash buffer. Bound proteins were separated by SDS-PAGE then transferred
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to a PVDF membrane, and subjected to Western blot analysis with anti- β-catenin, anti-AR, and
anti-Bag-1L.
Western Blot Analysis
Protein concentrations of lysate samples were determined via Bradford Assay using
Coomassie Plus Assay Kit according to the manufacturer’s instructions. Thirty µg of each sample
was loaded into a 10-well 4-12% Bis-Tris protein gel and transferred to a PVDF membrane. The
presence of AR was detected using mouse monoclonal anti-AR antibody (Santa Cruz), β-catenin
using mouse monoclonal anti-β-catenin (Santa Cruz), and Bag-1L using rabbit polyclonal antiBag1 (Protein Tech). All antibodies were alkaline phosphatase conjugated for use with the ImmunStar AP substrate upon exposure to X-Ray film.

2.2.3 Results
Bag-1L Synergizes with β-catenin to Potentiate AR Activity in the Same Manner as FKBP52
and this Synergy Occurs in a Hormone-Dependent Manner.
As Bag-1L is known to interact with β-catenin and previous studies have suggested that its
interaction with AR may be occurring at the BF3 surface, we hypothesized that Bag-1L may be
influencing AR activity in a way that is similar to FKBP52. Further, we speculated that it may also
be forming a complex with β-catenin and AR. Receptor-mediated luciferase assays indicate that
when combined with β-catenin, Bag-1L increases AR potentiation considerably more than when
AR is coupled with either protein alone, a trend also found to be true with β-catenin and FKBP52
(Figure 2.2.1). Co-immunoprecipitations conducted with mammalian cell lysates and using a flagtagged β-catenin illustrate the formation of a novel protein complex composed of Bag-1L, AR,
and β-catenin. Further inspection reveal that the formation of this complex may be dependent on

42

the presence of hormone (Figure 2.2.2). Taken together, this data may indicate the possibility of
the AR BF3 surface functioning as a regulatory region on the AR by β-catenin and several βcatenin binding partners.
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Figure 2.2.1 The Cochaperone Bag-1L Potentiates AR Activity in a Manner That Resembles the
Synergy Seen With β-catenin and FKBP52.

Bag-1L functions with β-catenin to potentiate AR activity. 22Rv1 cells were co-transfected with
AR, β-catenin, Bag-1L, the AR-inducible luciferase reporter plasmid, and the constitutively active
β-galactosidase reporter plasmid. Cells were induced with 10nM DHT. Following cell lysis, AR
expression was tested through a luciferase assay, followed by normalization to β-galactosidase
activity. Asterisk denotes statistically significant difference as compared to the vector alone control
(**p < 0.05). AR induction is significantly greater in the presence of β-catenin and Bag-1L as
compared to the empty vector (p = 0.0196).
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Figure 2.2.2 Novel Complex with Bag-1L, AR and β-catenin.

The cochaperone Bag-1L interacts with β-catenin and AR, forming a novel complex. 22Rv1 cells
were co-transfected with Bag-1L, AR, and flag-tagged β-catenin. Cells were induced with 10nM
DHT or equal volume of ethanol. Blots were probed for Bag-1L, AR, and β-catenin. Inputs shown
at bottom. All lanes were loaded with equal amounts of protein.
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2.3 DISCUSSION
The studies conducted here indicate that two AR cochaperones, FKBP52 and Bag-1L,
positively regulate receptor activity in vitro by working in concert with β-catenin. These
interactions are predicted to occur at the AR BF3 surface, a region found in the ligand binding
domain of AR. Previous studies using small molecules directed against the AR BF3 display loss
of interaction by AR BF3 binding partners, which includes FKBP52 and Bag-1L (19, 60).
Identifying these two cochaperones as positive regulators of AR activity further validates them as
potential targets for the treatment of prostate cancer.
FKBP52 relies on the presence of its proline-rich loop, and not its catalytic activity, to exert
its function on the AR. Receptor-mediated reporter assays and co-immunoprecipitations using an
FKBP52 loss-of-function mutant in which proline 119 in the proline-rich loop has been replaced
with leucine indicate loss of receptor potentiation and complex formation. Further, conducting
receptor-mediated reporter assays and co-immunoprecipitations in which Bag-1L has been
overexpressed in mammalian cells shows the same trend seen with FKBP52: significantly
increased receptor activity as well as the identification of a protein complex consisting of AR, βcatenin, and Bag-1L.
β-catenin acts as a coactivator of AR transcription and is involved in co-trafficking,
increasing cell proliferation, and prostate pathogenesis (39). The structure of β-catenin is largely
composed of 12 repeated three-helix structures termed the armadillo repeat region (ARM) flanked
by unstructured N- and C-terminal domains (44). Mutagenesis studies in which amino acids in the
ARM region known to interact with the ligand binding domain of the nuclear receptor LRH-1
found that these mutations disrupted the interactions between β-catenin and LRH-1. Due to the
structural similarity between the ligand binding domains of LRH-1 and AR, we hypothesized that

46

these mutated residues on β-catenin would also result in the inability to bind AR (42). Indeed, the
studies conducted here found that when key residues in the ARM region were mutated, there is a
loss of receptor potentiation and complex formation in co-immunoprecipitations.
These findings suggest that regulation of AR at the BF3 surface may rely on β-catenin
interaction with various cochaperones. Elucidating the mechanisms regulating the AR, particularly
at the BF3 surface, are critical for understanding the progression of prostate cancer.
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Chapter 3: Elucidating the Role of FKBP52 in the Regulation of Androgen Receptor
Activity
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3.1 Sub Aim 1: Development and Validation of FKBP52 Gene Deletion in the 22Rv1
Prostate Cancer Cell Line

3.1.1 Rationale
The use of cellular models have played an important role in elucidating the role of FKBP52
in regulating androgen receptor activity (32, 33, 37, 61). Our previous studies (Chapter 2) have
relied on the use of FKBP52 KO mouse embryonic fibroblasts to reveal the importance of various
domains needed for FKBP52 to regulate AR activity, and their implications in disease
development can be inferred from the data gleaned from those studies. However, there remains a
need to explore androgen receptor activity in an environment that represents the development of
prostate cancer. The goal of this aim was to establish and validate an FKBP52 KO cell line in
22Rv1 prostate cancer cells using the CRISPR/Cas9 system. This particular cell line was selected
for its expression of a truncated androgen receptor, one that lacks the ligand binding domain,
allowing the cell line to survive the knock out.

3.1.2 Materials and Methods
Use of CRISPR/Cas9 to Generate FKBP52 Knock Out in 22Rv1 Prostate Cancer Cells
Single guide RNA (sgRNA) and Cas9 enzyme were constructed and supplied by Synthego.
The gene target sequence, 5’-CCTACCTTTTCCCAGGTCAA, found in exon two of FKBP52 was
targeted using the following sequence on the sgRNA: 5’-CCUACCUUUUCCCAGGUCAA. To
induce the knockout, cells were transiently transfected with both the sgRNA and Cas9 enzyme to
produce a mixed pool of knock out cells. Single clones were isolated using limiting dilution.
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Clonal Selection and Expansion of Single Cell Colonies
After the pool of FKBP52 knock out cells were generated, individual clones were isolated
from the mixed population and expanded to identify cells which contained the knock out. To isolate
and expand the individual clones, cells were plated onto a 96-well plate at a concentration of 1
cell/well in 100µL of RPMI media plus 10% fetal bovine serum and were maintained at 5% CO2.
Wells were examined to ensure only one cell had been plated and wells containing multiple cells
were discarded. Once the single-cell population had grown confluent enough, cells were
transferred to increasingly larger vessels until they were expanded into a 25cm3 flask and knock
out was determined via Western blot.
Western Blot Analysis
To begin screening the expanded single-cell populations for the FKBP52 knock out, cells
were lysed with 200µL mammalian protein extraction reagent (M-PER) supplemented with HALT
protease inhibitor. Lysates were clarified by centrifuging in a 1.5mL microcentrifuge tube at
15,000 rpm at 4°C for 20 minutes. Protein concentrations of lysate samples were determined via
Bradford Assay using Coomassie Plus Assay Kit according to the manufacturer’s instructions.
Thirty µg of each sample was loaded into a 10-well 4-12% Bis-Tris protein gel and transferred to
a PVDF membrane. The presence of FKBP52 was detected using rabbit polyclonal anti-FKBP52
(Cell Signaling). Antibodies were alkaline phosphatase conjugated for use with the Immun-Star
AP substrate upon exposure to X-Ray film. The parental wild-type 22Rv1 cells were lysed
alongside the clones to be used as a positive control and the FKBP52 KO mouse embryonic
fibroblast cell line served as the negative control.
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PCR Verification of Potential Knock Out Candidates
Once potential knock out clones were identified via Western blot, PCR using genomic
DNA was used to further confirm the knock out. For each clone, genomic DNA was isolated using
PureLink Genomic DNA Minikit (Invitrogen). PCR was conducted using EconoTaq PLUS 2X
Master Mix (Lucigen) with 200ng of genomic DNA and using the following sequences for forward
and reverse primers, respectively: 5’-GTAACTGAATCTGGAGGGACAAGT and 5’AAGTGCTACCAGGTCTAAGAACTG. The parental wild-type 22Rv1 cells were amplified
alongside the clones to be used as a positive control.
Dose-Response Curves to Determine Hormone Requirement for FKBP52KO 22Rv1 Cells
To determine the hormone requirement for the newly identified FKBP52 KO cell line,
assess how it compares to the wild-type 22Rv1 cells, and test whether hormone requirements can
be restored to the wild-type when back-complemented with exogenous FKBP52, dose-response
curves were conducted using increasing concentrations of dihydrotestosterone (DHT).
Transfection was conducted as described by Samaniego et al. 2015 with some modifications. Cells
were seeded into a 6-well plate at a density of 2x105 cells/well and allowed to reach 80%
confluency prior to transfection. Cells were transfected using Lipofectamine 2000 at a DNA to
lipofectamine ratio of 1:3 in RPMI media lacking FBS according to the manufacturer’s
instructions. Transfections included the following plasmids: a constitutive β-galactosidase reporter
plasmid as a transfection control, a firefly luciferase reporter plasmid driven by the androgendependent probasin promoter, and a plasmid expressing FKBP52 to test for the back-complement
in the knock out. Four hours post-transfection, the media was changed to RPMI plus 10% charcoal
treated FBS. Twenty-four hours after being incubated with the charcoal-treated media, cells were
dosed with the following concentrations of DHT for 18 hours: 1pM, 10pM, 100pM, 250pM,
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500pM, 1nM, 10nM, 100nM. After incubation with hormone, cells were lysed with 150μL
mammalian protein extraction reagent (M-PER) supplemented with HALT protease inhibitor.
After clarifying the lysates, AR-mediated luciferase expression was quantified by mixing 40μL of
cell lysate with 100μL of luciferase assay reagent (Promega) in a 96-well plate and incubated at
room temperature for five minutes. β-galactosidase expression was quantified by adding 20μL cell
lysate with 100μL of Tropix Gal-Screen in a 96-well plate at room temperature for two hours.
Quantification of luminescence was conducted in a microplate luminometer with luminescence
measured as Relative Light Units (RLU) and normalized to β-galactosidase activity (RLU/ βgalactosidase) to control for transfection efficiency.
Statistical Analyses
All data are presented as mean ± standard deviation and is the average of duplicate
biological samples in a single dose-response curve. Each curve was repeated at least three
independent times and the graphs represent the average from all experiments. GraphPad Prism
software was used to generate the dose-response curves.
Immunofluorescent Staining and Confocal Microscopy
Wild-type and FKBP52 KO 22Rv1 cells were grown on glass slides using Nunc™ LabTek™ II Chamber Slide System (ThermoFisher) in RPMI media plus 10% fetal bovine serum and
allowed to reach 60-70% confluency. Once they reached the desired confluency, media was
changed to RPMI supplemented with 10% charcoal/dextran treated FBS. After a 24-hour
incubation with the charcoal-stripped media, cells were dosed with DHT (or equal volume of
vehicle control) for 18 hours using the following hormone concentrations as determined by the
previously conducted dose-response curve: 300pM for the wild-type cells and 11nM for the knock
out cells. To begin immunofluorescent staining, slides were washed once with PBS, followed by
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fixation in 4% (vol/vol) paraformaldehyde for 10 minutes at room temperature. Cells were
permeabilized in 0.25% (vol/vol) Triton X-100 for 10 minutes at room temperature and then
blocked for three hours in 5% (wt/vol) BSA at room temperature. Slides were then incubated
overnight at 4°C with anti-AR mouse monoclonal antibody (Santa Cruz Biotechnology) followed
by Alexa Fluor 488 conjugated goat-anti-mouse secondary antibody (Invitrogen). After three
washes with PBS, slides were mounted with ProLong™ Gold Antifade Mountant with DAPI
(Invitrogen). Confocal laser scanning microscopy was performed with a Zeiss LSM 700 confocal
microscope.
Xenograft Mouse Model and Tumor Formation
Animal studies
Animal studies were conducted at Clark-Atlanta University following the methods as
detailed by Patel et al. 2014 with some modifications (67). 22Rv1 and FKP52KO 22Rv1 cells (2
x 106) suspended in 100μL of serum-free RPMI 1640 media containing Matrigel (1:1 v/v; BD
Biosciences, San Jose, CA, USA) were injected subcutaneously into the lower flanks of 4-weekold castrated male C.B-17 SCID mice (Taconic Biosciences, Rensselaer, NY, USA) using a 27gauge syringe. The C.B-17 SCID mice were maintained at the Mercer University Vivarium. All
studies were approved by the Clark Atlanta and Mercer University Committee for the use and care
of animals.
Preparation of Tumor Cells
To prepare a fresh cell suspension for inoculation into mice, the wild-type and FKBP52
KO 22Rv1 cells were grown in RPMI media supplemented with 10% fetal bovine serum until
reaching 70-80% confluency. Three to four hours prior to harvesting, cells were washed once with
fresh media followed by a subsequent wash with PBS to remove dead and detached cells. After
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adding a minimum amount of trypsin/EDTA, cells were dispersed by adding complete medium
(5:1) and then centrifuged immediately at 405 x g for 5 min. After resuspending the cell pellet with
complete medium (1:1), cells were counted using a hemocytometer.
Tumor Inoculation
Prior to tumor inoculation, the work area was prepared by disinfecting all surfaces with
70% ethanol. To prepare the mice for inoculation, the injection area was cleaned and sterilized
with an alcohol pad. The freshly prepared cell suspension was agitated before being mixed with
Matrigel. One hundred microliters of the mixture containing 2 × 106 cells was injected
subcutaneously into the lower flank of each of the castrated C.B-17 SCID mice (Taconic
Biosciences) using a 27-gauge syringe. Tumor diameters were measured with digital calipers, and
the

tumor

volume

was

calculated
𝑉𝑜𝑙𝑢𝑚𝑒 =

each

week

using

the

equation:
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At the conclusion of the study, the mice were sacrificed, the tumors were surgically removed and
weighed, and the volume was measured.

3.1.3 Results
Schematic Illustration Indicating the Region on FKBP52 Targeted by CRISPR/Cas9.
Given the precision and effectiveness of the CRISPR/Cas9 system to manipulate genomes,
this technique was selected over other gene modification methods (68). As mentioned previously,
the 22Rv1 prostate cancer cell line was chosen due to its constitutive expression of the C-terminal
truncated receptor, allowing this cell line to survive the knock out of the FKBP52 gene. Figure
3.1.1 illustrates where the single guide RNA (sgRNA) targeted a region in exon two of FKBP52
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to induce a double strand break in the DNA by the Cas9 enzyme, effectively creating a deletion in
the FKBP52 gene.

Validation of the FKBP52 Knock Out in 22Rv1 Prostate Cancer Cells.
Once individual clones were isolated and expanded, potential knock out candidates were
initially screened via Western blot to examine FKBP52 protein expression levels. The clones
which displayed no expression of FKBP52 were then subjected to PCR using their genomic DNA
to validate the knock out (Figure 3.1.2 panel A). Once a full FKBP52 knock out clone was
identified and validated, a hormone dose-response curve was conducted to determine the hormone
requirement for the newly isolated FKBP52 knock out as compared to the wild-type parental
22Rv1 cells (Figure 3.1.2 panel B). The dose-response curve revealed that the FKBP52 KO 22Rv1
cells require 11nM DHT for androgen receptor induction, while the wild-type 22Rv1 cells require
300pM. To test whether hormone requirements in the FKBP52 KO cells can be restored to wildtype levels, the knock out cells were back-complemented with FKBP52 by transiently transfecting
cells with a plasmid expressing FKBP52. These cells required DHT at 120pM, hormone
concentrations comparable to that of the wild-type 22Rv1 cells (Figure 3.1.2 panel C).

Confocal Microscopy Reveals Differences in Receptor Nuclear Localization in the Absence of
FKBP52.
To assess for differences in androgen receptor localization when FKBP52 is present versus
when it is absent, immunofluorescence was performed on wild-type 22Rv1 cells and FKBP52 KO
22Rv1 cells induced with DHT or equal volume of ethanol as a vehicle control. In the wild-type
cells, nuclear translocation of the androgen receptor is evident when induced with DHT (Figure
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3.1.3 left panel). When the FKBP52 KO cells are induced with hormone, some receptor
localization in the nucleus is visible, however, there remains a significant amount of receptor in
the cytoplasm as well (Figure 3.1.3 right panel).

FKBP52 KO 22Rv1 Cells Fail to Form Tumors in Murine Animal Models.
To better understand the role of FKBP52 in tumor formation, our collaborators at ClarkAtlanta University, Dr. Jaideep Chaudhary’s group, investigated the ability of FKBP52 KO 22Rv1
cells to form tumors as well as the wild-type 22Rv1 cells. Xenograft mouse models were generated
by injecting FKBP52 KO 22Rv1 cells or wild-type 22Rv1 cells into 4-week-old castrated male
C.B-17 SCID mice. Tumor growth was monitored over the course of five weeks using digital
calipers and the volume was calculated using the equation mentioned above (Figure 3.1.4). The
data displays the weekly measurements of 4 wild-type 22Rv1 tumors and 4 FKBP52 KO 22Rv1
tumors. The asterisks denote a statistically significant difference between the wild-type and knock
out groups at each time point.
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Figure 3.1.1 Schematic Illustration Indicating the Region on FKBP52 Targeted by CRISPR/Cas9

The FKBP52 gene was knocked out of 22Rv1 cells using the CRISPR/Cas9 system. Single guide
RNA (sgRNA) targeted against a region in exon two of FKBP52 was transiently transfected with
the Cas9 enzyme to induce a double strand break in the DNA at that site, creating a mixed pool of
cells containing the deletion. To isolate and verify cells containing the knock out, limiting dilution
was conducted to create cell populations raised from a single origin cell that were confluent enough
to be screened via Western blot.
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Figure 3.1.2 Validation of the FKBP52 Knock Out in 22Rv1 Prostate Cancer Cells

A. To validate the deletion in the FKBP52 gene, genomic DNA was isolated from each clone and
PCR was conducted using primers that would amplify a region slightly downstream of the deletion
initiation site. Genomic DNA from the parental wild-type cells was amplified as a positive control.
B. Of the fifteen clones that were tested, one showed complete knock out of FKBP52 in the
Western blot and PCR screen. C. Following the verification, a dose-response curve was performed
to further determine the DHT requirement of the knock out. The FKBP52 KO 22Rv1 cells require
a DHT concentration of 11nM to achieve proper androgen receptor induction, a significantly
higher concentration than that of the wild-type cells which require only 300pM. To test whether
DHT requirements in the FKBP52 KO cells can be restored to that of the wild-type, we
exogenously expressed FKBP52 by transiently transfecting those cells with a plasmid expressing
FKBP52. These back-complemented cells displayed a DHT requirement of 120pM.
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Figure 3.1.3 Confocal Microscopy Reveals Differences in Receptor Nuclear Localization in the
Absence of FKBP52

To visualize any possible differences in the localization of the androgen receptor when FKBP52
is absent, indirect immunofluorescence was conducted on both the wild-type and KO cells with
and without hormone. Conditions in which there is no hormone present, androgen receptor in the
wild-type cells remain largely cytosolic (top left panel) with some receptor present in the nucleus.
In the presence of hormone, the wild-type cells exhibit distinct nuclear presence of the receptor
(bottom left). In the knock out cells, conditions in which there is no hormone present show a mostly
cytosolic receptor (top right). When the androgen receptor is induced with hormone, movement of
the receptor to the nucleus is visible, however there remains much more receptor in the cytosol
(bottom right).
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Figure 3.1.4 22Rv1 FKBP52 KO Cells Fail to Form Tumors in Murine Animal Models

Xenografts were implanted into immunodeficient mice and tumor growth was observed over the
course of five weeks. During the observation period, tumor diameters were measured using digital
calipers and the volume was calculated using the equation mentioned above. This data displays
the weekly measurements of 4 wild-type 22Rv1 tumors and 4 FKBP52 KO 22Rv1 tumors. The
asterisks denote a statistically significant difference between the wild-type and knock out groups
at each time point (** p < 0.05; ***p < 0.005). Significant differences were calculated by two-way
ANOVA followed by multiple comparisons test.
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3.2 SUB AIM 2: EXAMINATION OF THE ANDROGEN RECEPTOR CISTROME AND TRANSCRIPTOME
IN THE PRESENCE AND ABSENCE OF FKBP52

3.2.1 Rationale
Transcription factors such as the androgen receptor (AR) interact with the DNA to regulate
gene expression in mammalian cells. Cancer is marked by changes in transcriptional programs,
and the androgen receptor plays a key role in this process during the development of prostate
cancer (69, 70). As a nuclear receptor, the AR can have a significant effect on gene expression
through its interaction with chromatin and involvement with coregulators and the transcriptional
machinery (71–73). Previous studies have established a clear relationship between transcription
factor recruitment sites and gene regulation along with significant changes in the AR cistrome
during human prostate tumorigenesis (74, 75). Further, prostate cancer development associates
with transcriptional programs distinct from normal tissues and these transcriptional programs vary
depending on the receptor’s reliance on hormone in the tumor environment (76–80). Taking
together this information, it is evident that substantial changes occur in both the AR cistrome and
transcriptome during prostate cancer tumorigenesis. Understanding the mechanisms and key
contributors that induce these changes in expression profiles is important for the development of
effective therapeutic interventions against prostate cancer. To this end, we performed AR
chromatin immunoprecipitation and high-throughput DNA sequencing (ChIP-seq) in wild-type
and FKBP52 KO 22Rv1 cells to identify changes in the AR cistrome that may occur when FKBP52
is absent. To gain better insight into differences of gene expression profiles, we also conducted
RNA-seq in both wild-type 22Rv1 cells and FKBP52 KO 22Rv1 cells.
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3.2.2 Materials and Methods
ChIP-seq and DNA Binding Analysis in 22Rv1 cells
ChIP assays and DNA sequencing were conducted by Zymo Research using their EpiQuest
service, cell preparation and crosslinking were conducted by our lab. 22Rv1 wild-type and
FKBP52 KO cells were grown in RPMI 1640 media supplemented with 10% fetal bovine serum
until reaching desired confluency. Cells were then washed three times with warm PBS and
replaced with RPMI 1640 media supplemented with charcoal/dextran treated FBS for 24 hours.
Cells were then treated with either the hormone dihydrotestosterone (DHT) or an equal volume of
vehicle (ethanol) using the concentrations determined in Sub Aim 1 for each cell type. After
approximately 16 hours of treatment with hormone or vehicle, cells were harvested and washed
twice with PBS before being counted with a hemocytometer for a final cell count of 5 x 106
cells/mL. One mL of cells was crosslinked with 2mM disuccinimidyl glutarate for 45 minutes at
room temperature then washed three times by centrifuging at 3000 x g and resuspending in 1mL
PBS with 0.01% phenylmethylsulfonyl fluoride (PMSF). After the final wash, cells were
crosslinked once more with 1% formaldehyde for 10 minutes at room temperature. Cross-linking
was terminated with 0.125M glycine and cells were washed three times by centrifuging at 3000 x
g and resuspending the pellet in ice-cold PBS supplemented with PMSF and HALT protease
inhibitor cocktail. After the final wash, the supernatant was discarded and cell pellets were frozen
at -80°C until shipped to Zymo Research for the ChIP assay and DNA sequencing. Once at Zymo,
the chromatin was extracted and sheared to 100-700 bp in size. Resulting chromatin was incubated
with anti-Androgen Receptor polyclonal antibody (Millipore Cat # 17-10489, Lot 2752842) and a
negative control anti-IgG antibody (Millipore 12-370, Lot no. 297424). The AR ChIP assays were
performed in duplicate, triplicate or quadruplet using 30μg of chromatin and 5μg of antibody.
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Negative control IgG ChIP assays were repeated in triplicate. Samples underwent cross-linking
reversal and DNA was extracted. The samples were then re-sheared to 200-500 bp in size and the
concentrations of ChIP DNA were quantified by Qubit fluorometer and by qPCR using mouse
PSA enhancer region. DNA sequencing libraries were prepared using the ThruPLEX DNA-Seq
kit and were diluted to 2nM before being multiplexed and sequenced using 50bp reads on the NextGen Sequencing platform – HiSeq. All samples were processed through the same computational
pipeline developed at Zymo Research in Irvine, CA. Sequence tags were aligned with Bowtie 2
(v2.3.5) to build hg19 of the human genome. AR binding sites were generated with Model-Based
Analysis of ChIP-seq 2 (MACS2 v2.2.3) with a q-value cutoff of 0.05. Quality metrics of the ChIPseq data were calculated using ChIPQC (v1.18.2). Differentially bound sites were computed using
DiffBind (v2.10.0).
RNA Sequencing and Transcriptomic Analysis for 22Rv1 Cells
RNA sequencing was conducted by Zymo Research, cell preparation and RNA isolation
was conducted by our lab. 22Rv1 wild-type and FKBP52 KO cells were grown in RPMI 1640
media supplemented with 10% fetal bovine serum until reaching desired confluency. Cells were
then washed three times with warm PBS and replaced with RPMI 1640 media supplemented with
charcoal/dextran treated FBS for 24 hours. Cells were then treated with either the hormone
dihydrotestosterone (DHT) or an equal volume of vehicle (ethanol) using the concentrations
determined in Sub Aim 1 for each cell type. After approximately 16 hours of treatment with
hormone or vehicle, cells were harvested and washed twice with PBS before being counted with a
hemocytometer for a final cell count of 5 X 106 cells/mL. RNA was isolated using the Quick RNA
Miniprep kit from Zymo Research following the manufacturer’s instructions. RNA quality was
measured by Qubit fluorometer and TapeStation by Agilent prior to being sent to Zymo Research
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for sequencing and analysis. Total RNA-seq libraries were constructed from 500ng total RNA
from cDNA samples Total RNA-Seq libraries were constructed from approximately 500 ng of
total RNA. Libraries were prepared using the Zymo-Seq RiboFree Total RNA Library Prep Kit
(Cat # R3000) according to the manufacturer’s instructions. RNA-Seq libraries were sequenced
on an Illumina HiSeq to a sequencing depth of at least 60 million read pairs (150 bp paired-end
sequencing) per sample. NovaSeq paired-end 150-bp reads from Total RNA-Seq data files were
first adaptor trimmed, and then analyzed using the STAR program (version 2.6.1d) for alignment
of short reads to the Homo sapiens reference genome – hg38. Transcript counts were inferred from
alignment files. All transcripts with either 0 or 1 counts were removed. Gene expression was
measured using EdgeR (v3.26.5). The DESeq2 R package (v1.22.2) was used for differential
expression analysis using the gene feature. False discovery rate (FDR) threshold was set at 0.05
and Log2 fold change threshold was set at 0.585. Significantly altered genes between each
comparison group identified by RNA sequencing were clustered in function-related gene groups
using gene set enrichment analysis on gProfiler (v1.0.0). Gene ontology network was visualized
with Cytoscape (v3.1.2) and generated with Metscape.
Quantitative PCR
Quantitative PCR (qPCR) was used to assess expression of the top five up-regulated and
top five down-regulated candidate genes identified from RNA sequencing experiments. 22Rv1
wild-type and FKBP52 KO cells were plated into 6-well plates and grown in RPMI 1640 media
supplemented with 10% fetal bovine serum until reaching desired confluency. Cells were then
washed three times with warm PBS and replaced with RPMI 1640 media supplemented with
charcoal/dextran treated FBS for 24 hours. Cells were then treated with either the hormone
dihydrotestosterone (DHT) or an equal volume of vehicle (ethanol) using the concentrations
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determined in Sub Aim 1 for each cell type. After approximately 16 hours of treatment with
hormone or vehicle, cells were lysed and RNA was extracted using Trizol. RNA purity and
concentrations were calculated using NanoDrop2000. One microgram of RNA was subject to
cDNA synthesis using High-Capacity cDNA RT kit from Applied Biosystems according to the
manufacturer’s instructions. Quantitative PCR analysis was performed using PowerTrack SYBR
Green Master Mix (Applied Biosystems) and amplification reactions were carried out on Applied
Biosystems StepOnePlus PCR System using the following thermal profile: 95°C for 2 min (initial
denaturation), 95°C for 15s and 55°C for 30s (40 cycles), followed by 95°C for 15s and 60°C for
1 min (melt curve stage). Quantity mean values for each candidate gene were normalized to the
reference housekeeping gene GAPDH and the resultant normalized values were expressed relative
to the wild-type ethanol treated group. Statistical analysis was done using a one-way ANOVA with
Tukey’s multiple comparisons test. Data represent the mean of three independent experiments.
The following primers were used for the PCR reactions: GAPDH forward 5’GATTCCACCCATGGCAAATTC
CLDN11

forward

and

reverse:

5’-CTGGAAGATGGTGATGGGATT;

5’-CTCATTCTGCTGGCTCTCTG

and

reverse

5’-

AGTAGCCAAAGCTCACGATG; Colca1 forward 5’-CTGTAAGGACAGCAAGGATCTC and
reverse

5’–GAAACAAGGCCAACACAGAAG;

PLPP1

forward

5’-

GCAGCGATGGTTACATTGAATAC and reverse 5’-AACGAAGAGTGGCCTGAATAG; TJP3
forward

5’-GCAGAGGAAGCAGGACATTT

and

reverse

5’-

CTCAAAGTGAGTGCGGATGTAG; TUBB2B forward 5’- CGATGGATTCGGTTAGGTCTG
and

reverse

5’-GCCCTTGGCCCAGTTATT;

LGR4

forward

5’-

TTACTGAAGCGACGTGTTACC and reverse 5’-GCCACAGTCGTAGTAGAAATCC; MET
forward 5’- CCACGGGACAACACAATACA and reverse 5’-TAAAGTGCCACCAGCCATAG;
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TFCP2L1

forward

5’-AGAAGACTGACCGGGAGAA

and

reverse

5’-

TGTGAGGATGGTGGTTTCATAG; TPPP3 forward 5’-GCAAGAGATGAATGGCAAGAAC
and

reverse

5’-TTTGGAGAAGACGATGTCCAC;

TUNAR

forward

5’-

GATGAAGACAGAGGAGGTCAAG and reverse 5’-GGTTCAGAATGGTCCCGATAA.

3.2.3 Results
Changes in DNA Binding Sites of the Androgen Receptor When FKBP52 is Absent.
The androgen receptor is a transcription factor which, upon binding the hormone
dihydrotestosterone, translocates into the nucleus to bind DNA at its respective hormone response
elements (HREs) and regulate gene expression (2, 3). Our previous data have shown the
importance of FKBP52 in the regulation of androgen receptor activity, however, its influence in
receptor recruitment to the DNA remains unknown. Thus, we conducted ChIP-seq assays with the
goal of identifying changes in receptor DNA binding when FKBP52 is present compared to when
it is absent. Using both wild-type (WT) and FKBP52 KO 22Rv1 cells (KO), ChIP-seq was
conducted when the cells were treated either with the hormone DHT or an equal amount of vehicle,
ethanol. Within the four treatment groups (WT-ethanol, WT-DHT, KO-ethanol, KO-DHT), there
are distinct difference in AR DNA binding. Most notably, when comparing WT-DHT with KODHT, there is an 11-fold increase in the number of DNA sites upon which the receptor binds, with
site increases from 1,813 to 20,552 (Figure 3.2.1).

Changes in Gene Expression Levels When FKBP52 is Absent.
As mentioned above, changes in androgen receptor transcriptional programs during
prostate cancer development are well known, however the specific components leading to these
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changes are still being identified. Our ChIP-seq data indicate significant changes to AR DNA
binding when FKBP52 is absent (Figure 3.2.1). To determine if these changes correlate to
changes in gene expression, we conducted RNA-seq using wild-type and FKBP52 KO 22Rv1
cells under conditions in which they have been treated with either DHT or ethanol. A heatmap
illustrating the log transformed normalized gene expression for each treatment group (WT-DHT,
WT-etOH, KO-DHT, and KO-etOH) reveals key differences in genes that are up- and downregulated, especially when comparing WT-DHT and KO-DHT (Figure 3.2.2). Pathway analysis
of gene functions affected by the FKBP52 knock out demonstrate a clear disruption in cellular
functions (Figure 3.2.3). To validate the data from the RNA-seq experiments, qPCR was
conducted on the top ten up- and down-regulated genes (Figure 3.2.4).
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Figure 3.2.1 Differences in DNA Binding Sites in Wild-type and FKBP52 KO 22Rv1 Cells

ChIP-seq was conducted on both wild-type and FKBP52 KO 22Rv1 cells which were treated
with either DHT or vehicle, ethanol. This Venn diagram displays the individual binding sites on
the DNA for each condition (WT-ethanol, WT-DHT, KO-ethanol, KO-DHT) as well as DNA
binding site overlaps for various comparison groups.
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Figure 3.2.2 Heatmap Illustrating Differences in Gene Expression in Wild-type and FKBP52 KO
22Rv1 cells

Heatmap of the log transformed normalized expression of genes up- and down-regulated in wildtype and FKBP52 KO 22Rv1 cells. RNA-seq was conducted on both wild-type and FKBP52 KO
cells, treated with either DHT or ethanol. After RNA isolation and library preparation, RNA-Seq
libraries were sequenced on an Illumina HiSeq to a sequencing depth of at least 60 million read
pairs (150 bp paired-end sequencing) per sample. NovaSeq paired-end 150-bp reads from Total
RNA-Seq data files were first adaptor trimmed, and then analyzed using the STAR program
(version 2.6.1d) for alignment of short reads to the Homo sapiens reference genome – hg38.
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Transcript counts were inferred from alignment files. All transcripts with either 0 or 1 counts were
removed. Gene expression was measured using EdgeR (v3.26.5). The DESeq2 R package
(v1.22.2) was used for differential expression analysis using the gene feature. False discovery rate
(FDR) threshold was set at 0.05 and Log2 fold change threshold was set at 0.585. Significantly
altered genes between each comparison group identified by RNA sequencing were clustered in
function-related gene groups using gene set enrichment analysis on gProfiler (v1.0.0).
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Figure 3.2.3 Pathway Analysis Indicates Distinct Changes in Cellular Functions When FKBP52
is Absent

Enriched ontology clusters for wild-type cells with and without hormone and FKBP52 KO cells
with and without hormone. Each enrichment term is represented by a circle node, where its size
is proportional to the number of input genes which fall into that term, and its color represent its
cluster identity.
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Figure 3.2.4 Validation of RNA-seq data by qPCR

To validate the RNA-seq data, we performed qPCR on the top five up- and down-regulated
genes. RNA was isolated using Trizol from wild-type and FKBP52 KO 22Rv1 cells which were
treated with either DHT or ethanol. Quantity mean values for each candidate gene were
normalized to the reference housekeeping gene GAPDH and the resultant normalized values
were expressed relative to the wild-type ethanol treated group. Statistical analysis was done
using a one-way ANOVA with Tukey’s multiple comparisons test. Data represent the mean of
three independent experiments. The top row displays the five genes which were found to be
down-regulated in the FKBP52 KO cells, while the bottom row displays the five genes which
were up-regulated in the FKBP52 KO cells.
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3.3 DISCUSSION
Previous studies have established that FKBP52 is a positive regulator of AR activity in
cellular and whole animal models and the data from Chapter 2 reveal that the cochaperone relies
on the region found in its proline-rich loop to exert its function on the receptor. By using the
CRISPR/Cas9 system to knock out FKBP52 from 22Rv1 mammalian cells, we have been able to
study changes in AR activity in an environment that resembles prostate cancer. When FKBP52 is
knocked out, the hormone requirement for AR increases from 300pM in the wild-type cells to
11nM in the knock out cells. When back-complemented with exogenously expressed FKBP52,
hormone requirement is similar to that of the wild-type cells, 120pM. In studies where we
examined intracellular receptor localization, we found that when FKBP52 is absent and the cells
are treated with hormone, the AR remains largely cytosolic as opposed to the canonical receptor
localization of translocating into the nucleus upon exposure to hormone. These results suggest that
FKBP52 assists in receptor localization when the receptor is induced with hormone. Further,
xenografts established in mice using the knock out cells revealed that they fail to form tumors as
well as the wild-type 22Rv1 cells, further validating the development FKBP52 as a drug target.
Our establishment and validation of an FKBP52 KO cell line in mammalian prostate cancer
cells allowed us to gain a deeper understanding of how the cochaperone is regulating AR activity.
Our confocal data demonstrated that AR induced with hormone does not readily translocate into
the nucleus when FKBP52 is knocked out. However, our ChIP-seq data revealed that the few
receptors which are nuclear, are being recruited to a vastly increased number of sites on the DNA.
Sites of DNA binding for AR are significantly altered in FKBP52 KO cells treated with hormone,
with a total of 20,552 DNA binding sites as compared to the wild-type cells which total 1813 sites.
This, however, does not translate to increased gene expression, as our RNA-seq data indicated
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diminished expression levels in the knock out cells as compared to the wild-type. The pathway
analysis examining differences in cellular functions also displayed a marked decrease in cellular
functions in the knock cells as opposed to the wild-type.
The studies conducted in this chapter illuminate the role of the FKBP52 cochaperone in
regulating androgen receptor activity, from receptor localization to DNA binding to gene
expression. Taken together, this data suggests that AR activity may be much more reliant on
regulation by FKBP52 than was previously known. Insight into how this cochaperone is capable
of regulating AR activity further validates its use as a potential target for the treatment of prostate
cancer.
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Chapter 4: Validation of FKBP52 as a Therapeutic Target for the Treatment of Prostate
Cancer
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4.1 RATIONALE
Drugs targeting novel androgen receptor (AR) surfaces or novel receptor signaling
mechanisms are promising alternatives for the treatment of androgen-resistant prostate cancer (61).
The 52 kDa FK506 binding protein (FKBP52) is an Hsp90 cochaperone known to be a positive
regulator of AR activity in both cellular and animal models, making it an ideal candidate for the
treatment of prostate cancer. Our lab has previously identified a small molecule, MJC13, that
inhibits FKBP52-specific AR activity (61, 81). MJC13 was tested in early and late-stage prostate
cancer cells and was demonstrated to inhibit AR-dependent gene expression and androgenstimulated prostate cancer cell proliferation (61, 82). This small molecule targets a region on the
ligand binding domain of AR termed the BF3 surface, a surface now known to be the FKBP52
interaction site. MJC13 is able to inhibit AR function by preventing dissociation of the Hsp90AR-FKBP52 complex in the cytoplasm, inhibiting nuclear translocation of the receptor (61, 82).
Currently, MJC13 is used at a concentration of 30µM to effectively inhibit receptor function in
mammalian cell lines. Therefore, to better improve dosing and solubility of MJC13, our lab has
partnered with a biochemistry group, MAIA Biotechnology, to aid in the synthesis of MJC13
analogues. The goal of this specific aim is to develop small molecules with greater ability to inhibit
FKBP52-specific AR activity to increase efficacy, reduce toxicity, and ensure bioavailability of
the compound. Our lab has developed and published extensively on a 4-hour yeast-based, receptormediated β-galactosidase reporter assay for use in screening compound libraries for receptorspecific inhibitors (83, 84). This same assay was used in the initial identification of MJC13 and
will serve as the primary means to screen new compounds. The MJC13 analogues generated by
MAIA Biotechnology will be assessed for the ability to inhibit AR-mediated reporter expression
in full dose-response curves in the presence or absence FKBP52 and the hormone
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dihydrotestosterone (DHT). Any molecules that display AR inhibition in the presence of FKBP52
and DHT with a half-maximal inhibitory concentration (IC50) less than 1µM will be moved forward
to in vivo absorption, distribution, metabolism, and excretion (ADME) studies.

4.2 MATERIALS AND METHODS
Synthesis and Preparation of Lead Molecules
Working in collaboration with MAIA Biotechnology, MJC13 analogues were constructed
using the chemical structure of MJC13 as a scaffold. Synthesis of new compounds was completed
by manipulation of either the left-hand side R-group, middle R-group, or right-hand side R-group
of MJC13. To prepare the compounds for screening, a 10mM stock solution was made by
dissolving each analogue in DMSO and then diluting down to the following working stocks: 5mM,
1mM, 500µM, 100µM, 50µM
Yeast Strains
The yeast strains used in this assay were a generous gift from David Smith. Both strains
had been previously transformed to express the androgen receptor and the LacZ enzyme to measure
β-galactosidase activity. The experimental strain, DSY-1555, was transformed with a plasmid
expressing FKBP52 while the control strain, DSY-1553, was transformed with an empty
expression vector. The hormone requirements are 10nM final concentration for DSY-1555 and
100nM final concentration for DSY-1553
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Receptor-Mediated Reporter Assay in Yeast
Yeast reporter assays utilizing Saccharomyces cerevisiae have routinely been used in our
lab to record androgen receptor activity by means of measuring β-galactosidase. Standard
procedures as detailed by Balsiger et al. 2009 were followed with modifications when necessary.
Independent isolates of DSY-1553 and DSY-1555 were grown overnight in 10mL of selective
growth media lacking leucine, uracil, and tryptophan in a shaking water bath incubator at 30°C.
The following morning, the optical density (OD600) of the overnight cultures was determined via
spectrophotometry. To ensure that the yeast were in logarithmic growth phase, cultures were
diluted and growth was monitored in 20-minute increments until an OD600 of 0.08 was reached.
Next, 100µL of each culture was transferred to an opaque 96-well plate and then treated with 1µL
of increasing concentrations of either MJC13, MJC13 analogues, or 1µL DMSO. The final
concentrations of MJC13 and the analogues used in this assay were: 0, 0.5µM, 1µM, 5µM, 10µM,
50µM. After adding the drug, the 96-well plate was covered to avoid evaporation and incubated
for 30 minutes at 30°C. Once the 30-minute incubation was complete, 1µL dihydrotestosterone
(DHT) was then added to each well and incubated for an additional two hours at 30°C with the
plate covered. To measure β-galactosidase activity, 100µL of Tropix Gal-Screen substrate and
buffer (Applied Biosystems) was added to each well, plates were again covered to avoid
evaporation, and incubated for two hours in the dark at room temperature. Post two-hour
incubation, the chemiluminescent signal was detected using a microplate luminometer (BioTek).
Statistical Analysis of Reporter Assay Data
All data are represented as mean ± standard deviation and is the average of duplicate
biological samples in a single experiment. Initial screens were conducted once, and subsequent
screens with potential lead compounds were repeated at least three times before submission for
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ADME studies. For each yeast strain (AR + FKBP52 or AR + empty vector) the data was
normalized to its respective DHT+DMSO condition. GraphPad Prism 8 software was used to
generate the graphs.

4.3 RESULTS
Yeast Assay Identifies 5 MJC13 Analogues with Greater Ability to Inhibit FKBP52-Specific
AR Activity.
Yeast bioassays have been extensively used to study receptor activity and to characterize
the role of receptor-associated cochaperones (30, 32, 38, 56, 83). Given the ability to quickly
screen large compound libraries, we employed this assay to identify potential lead MJC13
analogues for the FKBP52-specific inhibition of androgen receptor activity. A graphic illustration
of the assay is described in Figure 4.1.1. Briefly, log-phase yeast cells are plated onto a 96-well
plate then dosed with increasing concentrations of drug before being incubated at room
temperature for 30 minutes. After the 30-minute incubation, hormone is added and plates are
further incubated for two hours at room temperature before adding Tropix Gal-Screen substrate
and buffer to read the β-galactosidase activity on a plate luminometer.
Working with MAIA Biotechnology, we developed a total of 178 novel compounds based
on the structure of MJC13 (Figure 4.1.2). Modifications to MJC13 were made to R-groups found
on the left-hand side, the middle, or the right-hand side and then tested for their ability to inhibit
androgen receptor activity. Of the compounds screened, five displayed greater ability to inhibit
FKBP52-specific AR activity when compared to MJC13 (Figure 4.1.3).
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DSY-1555

DSY-1553

Figure 4.1.1 Schematic Representation of Yeast-Based Screen for FKBP52-Specific AR
Inhibition.

Overnight cultures of yeast strains DSY-1553 and DSY-1555 were grown in 10mL of synthetic
compete media lacking the amino acids leucine, uracil, and tryptophan. The following day, cultures
were diluted to an OD600 of 0.08 and allowed to reach logarithmic growth. 100µL of yeast are
plated onto a 96-well plate and then dosed with 1µL drug for 30 minutes, then 1µL hormone for
two hours. After incubating with drug and hormone at room temperature, β-galactosidase substrate
and buffer are added to each well for two hours in order to read the chemiluminescent signal via a
plate luminometer.
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Figure 4.1.2 Utilizing MJC13 as a Scaffold to Create Novel Compounds for Testing.

Using MJC13 as a scaffold chemical structure, modifications were made at one of three R-groups
present on MJC13: the left-hand side, the middle, or the right-hand side. Compounds arrived from
MAIA Biotechnology containing various changes at these positions to be screened using our fourhour yeast bioassay.
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Figure 4.1.3 Five MJC13 Analogues Display Greater Potency of Receptor Inhibition.

Of the 178 compounds screen, five showed receptor inhibition that was more effective than
MJC13. Dose response curves for MJC13 and the five newly identified compounds indicate some
molecules are more effective than MJC13 at inhibiting FKBP52-specific receptor activity. Shown
at top left is MJC13 which has an IC50 of 0.5585 µM. The five novel compounds that follow all
have an IC50 less than 0.5 µM, with MJC L-X29 having the lowest IC50 at 0.16µM. The five newly
identified compounds will need to be assessed for absorption, distribution, metabolism, and
excretion (ADME) in mice.
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4.4 DISCUSSION
MJC13 is a small molecule first identified by our lab to inhibit FKBP52-specific androgen
receptor activity. By targeting a region on AR that is known to be an FKBP52 interaction site,
MJC13 effectively prohibits dissociation of the Hsp90-AR-FKBP52 complex, resulting in
decreased receptor localization to the nucleus and inhibiting AR-dependent gene expression.
Although effective, there remains a need to improve drug efficacy. By working in collaboration
with MAIA Biotechnology, we took the chemical structure of MJC13 to use as a scaffold for the
synthesis of MJC13 analogues. Modifications were conducted on one of the R groups shown in
Figure 4.1.2 with the goal of synthesizing novel small molecules with improved efficacy and
absorption in animal models. To quickly and effectively screen these analogues for FKBP52specific inhibition of AR activity, we employed our lab’s four-hour yeast-based assay (Figure
4.1.1). Through this method, we were able to screen 178 MJC13 analogues and identified five lead
compounds with an IC50 less 0.5µM (Figure 4.1.3). Each of these five analogues displayed
FKBP52 specificity and were effective at concentrations lower than MJC13. To further assess their
efficacy in vivo, absorption, distribution, metabolism, and excretion (ADME) studies will be
conducted in mice.
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Chapter 5: Conclusions
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5.1 THE COCHAPERONES FKBP52

AND

BAG-1L WORK

IN

TANDEM

WITH ß-CATENIN TO

POSITIVELY REGULATE ANDROGEN RECEPTOR ACTIVITY
The data presented in Chapter 2 illustrate that androgen receptor (AR) activity is positively
regulated in vitro by two cochaperones, FKBP52 and Bag-1L, when they each interact with βcatenin. When FKBP52 and β-catenin synergize, AR activity is significantly increased, and this
upregulation is especially evident when the hormone dihydrotestosterone is present (32, 37).
Further investigation into these interactions revealed that a region on FKBP52, known as the
proline-rich loop, is largely responsible for this synergy to take place (Figure 2.1.1). More
specifically, we were able to determine that the proline present at residue 119 is critical for
FKBP52 to form a complex containing β-catenin and AR (Figure 2.1.2). The proline-rich loop is
a region found near the N-terminus of FKBP52, overhanging the catalytic pocket for which most
of the functions of the FKBPs rely on and was previously believed to be integral to FKBP52 action
on AR (37, 38). The data shown here confirm the role that the proline-rich loop region, and not
the catalytic pocket, has on influencing AR activity.
To better understand how β-catenin was participating in these interactions, we investigated
which domains on β-catenin were necessary to induce this synergy with FKBP52. It is widely
suggested that the armadillo repeat region (ARM) on β-catenin is the primary contact surface for
interactions with AR (42). Using various β-catenin mutants with amino acid substitutions in the
ARM region, we were able to determine that when tryptophan 383 was changed to alanine, there
is a significant decrease in receptor activity (Figure 2.1.3). This same mutant, when subjected to
co-immunoprecipitation, fails to form a complex with AR and FKBP52 (Figure 2.1.4). Further
inspection of this data suggests that when β-catenin is unable to form the canonical complex with
AR and FKBP52, there is also reduced amounts of AR in this complex, implying that β-catenin is
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serving as a central mediator between the two proteins and may be a requirement for this complex
to form.
Pursuing the idea of β-catenin acting as the central mediator in AR interactions with
cochaperones, we explored other cochaperones for their potential to interact with β-catenin to
upregulate AR activity. The longest of the four Bag-1 isoforms, Bag-1L has been widely linked to
regulation of the AR activity and has recently emerged as a target for the treatment of prostate
cancer (19, 62, 63, 65, 66). The data shown in this chapter is the first to demonstrate that Bag-1L
does indeed work in concert with β-catenin to upregulate AR activity, much in the same manner
as seen with FKBP52 (Figure 2.2.1). Coimmunoprecipitations also indicate a novel complex
formation consisting of β-catenin, AR, and Bag-1L and also reveal that this complex formation is
dependent on the presence of the hormone DHT (Figure 2.2.2).
Taken together, these results highlight the importance of β-catenin in regulating AR
activity and also demonstrate the influence cochaperones have on receptor function, making them
highly attractive targets for the treatment of prostate cancer.

5.2 ANDROGEN RECEPTOR CISTROME AND TRANSCRIPTOME ARE SIGNIFICANTLY REGULATED
BY FKBP52

Previous studies have clearly demonstrated the changes which occur to the AR cistrome
and transcriptome during the development of prostate cancer (74, 75, 79). The studies conducted
in this chapter are the first to acknowledge FKBP52’s contribution to these changes. As an Hsp90
cochaperone, FKBP52 has long been associated with aiding in the folding and maturation of
steroid hormone receptors and has been found to be integral in male reproductive tissues of mice
(33, 37). Our lab was the first to document that FKBP52 positively regulates AR activity in vitro

86

when coupled with the AR coactivator, β-catenin (32). Together, this data implies FKBP52 has
functions that extend beyond its canonical role of an Hsp90 cochaperone.
The data presented in Chapter 3 Sub Aim 1 demonstrate considerable changes in AR’s
hormone requirement when FKBP52 is absent from 22Rv1 prostate cancer cells (Figure 3.1.2).
Further, our confocal microscopy images illustrate that receptor localization into the nucleus upon
induction with hormone is disrupted in the absence of FKBP52, with the receptor remaining largely
cytosolic (Figure 3.1.3). Xenografts established in immunodeficient mice using the FKBP52 KO
22Rv1 cells exhibited notably decreased tumor size when compared to xenografts of the wild-type
cells (Figure 3.1.4). This data suggests that intracellular functions of the receptor are much more
reliant on FKBP52 than was previously known.
Chapter 3 Sub Aim 2 sought to examine the effects FKBP52 may have on AR recruitment
to the DNA after hormone induction as well as its influence on AR-dependent gene expression.
Under typical conditions, after being induced by hormone, AR translocates into the nucleus where
it binds its respective hormone response elements to stimulate transcription of target genes. Our
study found that when FKBP52 is absent, AR binding of the DNA is altered drastically (Figure
3.2.1). While there is movement into the nucleus, our ChIP-seq experiment found that DNA
binding sites for AR increased by 11-fold, from 517 to 20,552. Though we were able to find
increased binding to the DNA, this did not translate into increased gene expression. Our RNA-seq
studies found that gene expression in cells where FKBP52 has been knocked out and the receptor
was induced with hormone, there was less gene expression than the wild-type cells (Figure 3.2.2).
Pathway analysis also revealed changes in cellular functions of the cells, with a decrease in cell
functions in the absence of FKBP52 (Figure 3.2.3).
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The data in this chapter illuminate the importance of FKBP52 in regulating AR activity,
particularly in tumor formation, receptor localization, DNA binding, and gene expression. These
studies offer more insight into FKBP52’s role as a cochaperone and further supports studies
targeting this protein as a therapeutic treatment for prostate cancer.

5.3 ANALOGUES

OF

MJC13 VALIDATE FKBP52

AS A

DRUGGABLE TARGET

FOR INHIBITING

ANDROGEN RECEPTOR ACTIVITY IN YEAST
The data presented in Chapters 2 and 3 demonstrate that FKBP52 plays an integral role in
regulating AR activity and further illustrate the importance of pursuing small molecules targeting
this cochaperone for the treatment of prostate cancer. Indeed, our lab has previously patented
MJC13 which is known to inhibit FKBP52-specific AR activity (61, 81, 82). When tested in early
and late-stage prostate cancer cells, MJC13 was demonstrated to inhibit AR-dependent gene
expression and androgen-stimulated prostate cancer cell proliferation (61, 82). MJC13 is able to
effectively inhibit receptor signaling by targeting and binding to a region on the AR hormone
binding domain, the BF3 surface. This region is believed to be the regulatory surface for FKBP52
to exert its action on AR. To be effective in mammalian cell lines, a concentration of 30µM is
required, leaving room for improving the efficacy of MJC13. To this end, our lab partnered with a
biotechnology company, MAIA Biotechnology, to begin developing more potent molecules.
Using the chemical structure of MJC13 as the framework, the different R groups present on MJC13
were manipulated to create novel molecules (Figure 4.1.2). Making use of our lab’s four-hour yeast
assay, we were able to quickly and thoroughly screen all 178 newly synthesized molecules for
their ability to hinder AR activity in a manner that is specific to FKBP52 (Figure 4.1.1) This highthroughput yeast-based screen revealed five of the analogues had a half-maximal inhibitory
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concentration, or IC50, less than MJC13 (Figure 4.1.3). Interestingly enough, these five analogues
all had changes made to the left-hand side R-group of MJC13, suggesting this region may play an
important role in specifically hindering FKBP52 activity.
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